Lawrence H. Price, MD
CURRICULUM VITAE LAWRENCE H. PRICE, M.D.
PERSONAL INFORMATION
Citizenship: United States. Work Address: Butler Hospital, Dept. of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, 345 Blackstone Blvd., Providence, RI 02906. Work Tel: (401) 455-6533; (401) 455-6534 (FAX). E-mail: [email protected]
EDUCATION:
Undergraduate: Univ. of Michigan, Ann Arbor, MI, B.S. (Psychology), 1974. Medical School: Univ. of Michigan, Ann Arbor, MI, M.D., 1978.
POSTGRADUATE TRAINING
Internship: Intern in Internal Medicine, Norwalk Hosp. (in affiliation with Yale Univ. Schl. of Medicine), Norwalk, CT, 1978-1979. Residency: Resident in Psychiatry, Yale Univ. Schl. of Medicine, New Haven, CT, 1979-1982. Chief Resident in Psychiatry, Adult Treatment Unit, Yale-New Haven Hosp., New Haven, CT, 1981. Chief Resident in Psychiatry, Consultation/Liaison Service, Yale-New Haven Hosp., New Haven, CT, 1982. Post-Residency: Instructor/Chief Resident in Psychiatry, Yale Univ. Schl. of Medicine and Assistant Unit Chief, Adult Treatment Unit, Yale-New Haven Hosp., New Haven, CT, 1982-1983.
HONORS AND AWARDS
National Merit Scholar, 1970-1974. Honors Program in Psychology, Univ. of Michigan, 1970-1974. Phi Eta Sigma National Freshman Honor Society (invitation), 1971. William J. Branstrom Prize (for "outstanding freshman performance"), Univ. of Michigan, 1971. B.S. with High Distinction and Highest Honors in Psychology, Univ. of Michigan, 1974. Phi Beta Kappa, Univ. of Michigan, 1974. Outstanding Intern Award, Norwalk Hosp. (in affiliation with Yale Univ. Schl. of Medicine), 1979. Laughlin Fellow (for "most promising resident"), American College of Psychiatry, 1981. Laughlin Award for Merit (for "professional achievement, dedication, and scholarship"), National Psychiatric Endowment Fund, 1982. Stephen Fleck Faculty Award (for "exemplary physician and clinical teacher"), Department of Psychiatry, Yale Univ. Schl. of Medicine, 1985. Sigma Xi Scientific Research Society, Yale Univ., 1988. Award for Excellence in Teaching, Yale Psychiatry Residents Association, Yale Univ. Schl. of Medicine, 1991. Citation, Best Doctors, Best Doctors, Inc., Aiken, SC, 1994-2012. Outstanding Teaching Award in Medical School Education, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 1997. Master of Arts ad eundem, Brown Univ., 1998. Outstanding Teaching Award in General Psychiatry, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 1999. Research Mentor Award, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 2000, 2006.
1
Lawrence H. Price, MD
Citation, top 10 authors of high-impact papers in psychiatry, 1990-1999, Institute for Scientific Information, Philadelphia, 2000. Dean's Teaching Excellence Award (for "exemplary teaching in Bio 510: Clerkship in Psychiatry"), Brown Medical School, 2001. Faculty Development Mentorship Award in Psychopharmacology, Janssen Pharmaceutica Psychiatry Distinguished Awards Program, 2003. Citation, America's Top Doctors, Castle Connolly Medical Ltd, NY, NY, 2003-2012. Citation, 5th Anniversary America's Top Doctors, Castle Connolly Medical Ltd, NY, NY, 2011. Distinguished Fellow, American Psychiatric Association, 2004. Citation, Highly Cited Researcher in psychology/psychiatry, 1981-1999, Thomson ISI, Philadelphia, http://isihighlycited.com/, 2004. Faculty Mentoring Award, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 2005. APEX 18th Annual Award for Publication Excellence, “Newsletter Writing -- Brown University Psychopharmacology Update,” Communications Concepts, Inc, Springfield, VA, 2006. Citation, top 4 psychiatrists for men, Northeast, Men’s Health, April, 2007. Citation, top 4 psychiatrists for women, Northeast, Women’s Health, November, 2008. Annual Awards Competition Gold Award, Second Place, “Best Technical Article -- Brown University Psychopharmacology Update,” The Newsletter on Newsletters, 2011. Fellow, American College of Neuropsychopharmacology, 2011.
PROFESSIONAL LICENSES AND BOARD CERTIFICATION
Diplomate, National Board of Medical Examiners, 1979. Licensed Medical Doctor, Connecticut Medical Examining Board, State of Connecticut, 1980. Diplomate, American Board of Psychiatry and Neurology, 1983. Licensed Medical Doctor, Board of Medical Licensure and Discipline, State of Rhode Island and Providence Plantations, 1996.
ACADEMIC APPOINTMENTS
Assistant Professor of Psychiatry, Yale Univ. Schl. of Medicine, New Haven, CT, 1983-1989. Associate Professor of Psychiatry, Yale Univ. Schl. of Medicine, New Haven, CT, 1989-1996. Professor of Psychiatry and Human Behavior, The Warren Alpert Medical Schl. of Brown Univ., Providence, RI, 1996-.
HOSPITAL APPOINTMENTS
Attending psychiatrist, Yale-New Haven Hosp., New Haven, CT, 1982-83; 1988-1996. Attending psychiatrist, Connecticut Mental Health Center, New Haven, CT, 1983-1996. Associate Unit Chief, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1983-1988. Co-Chief, Depression Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1984-1987. Chief, Inpatient Division, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1984-1996. Director, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1988-1996. Chief, Depression Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1988-1995. Attending psychiatrist, Butler Hosp., Providence, RI, 1996-. Director of Research, Butler Hosp., Providence, RI, 1996-. Chief, Mood Disorders Program, Butler Hosp., Providence, RI, 1996-1997. Attending psychiatrist, Kent Hosp., Warwick, RI, 1997-.
2
Lawrence H. Price, MD
Medical Director, Butler Hosp., Providence, RI, 1997-8. Clinical Director, Butler Hosp., Providence, RI, 1998-. Interim Chief, General Adult Treatment Unit, Butler Hosp., Providence, RI, 2007. Graduate Medical Education Designated Institutional Official, Butler Hosp., Providence, RI, 2009-.
OTHER APPOINTMENTS
Clinical psychiatric practice, Yale Dept. of Psychiatry Practice Plan, 1982-1996. Clinical psychopharmacology consultant, Yale Psychiatric Institute, New Haven, CT, 1984-91. Ad hoc grant reviewer -- Mental Health and Behavioral Sciences Research Advisory Group, Veterans Administration; British Medical Research Council; Ontario Mental Health Foundation; Medical Research Council of Canada; Obsessive Compulsive Foundation; Medical Research Service, Dept of Veterans Affairs; Israel Science Foundation; Lifespan Developmental Grant Program; Richard B. Salomon Faculty Research Awards, Brown Univ.; NARSAD; Qatar National Research Fund; Alberta Heritage Foundation for Medical Research; German Federal Ministry of Education and Research. Reviewer – Alcoholism: Clinical and Experimental Research; American Journal of Physiology: Regulatory, Integrative and Comparative Physiology; American Journal of Psychiatry; Anxiety; Archives of General Psychiatry; Behavior Genetics; Biological Psychiatry; Bipolar Disorders; BMC Psychiatry; Clinical Drug Investigations; CNS Drugs; CNS Spectrums; Depression and Anxiety; Drugs; Drugs & Aging; Experimental and Clinical Psychopharmacology; Expert Opinion on Drug Safety; Expert Opinion on Pharmacotherapy; Expert Review of Medical Devices; Expert Review of Neurotherapeutics; Future Neurology; Harvard Review of Psychiatry; Hormones and Behavior; International Clinical Psychopharmacology; International Journal of Neuropsychopharmacology; Journal of Affective Disorders; Journal of Aggression, Maltreatment & Trauma; Journal of Autism and Developmental Disorders; Journal of Child and Adolescent Psychopharmacology; Journal of Clinical Psychiatry; Journal of Clinical Psychopharmacology; Journal of Gambling Studies; Journal of Nervous and Mental Disease; Journal of Neurochemistry; Journal of Neuropsychiatry and Clinical Neurosciences; Journal of Pediatrics; Journal of Psychiatric Research; Lithium; Molecular Psychiatry; Neuropharmacology; Neuropsychobiology; Neuropsychopharmacology; New England Journal of Medicine; Nicotine and Tobacco Research; Patient Care; Pharmacology, Biochemistry and Behavior; Pharmacology & Toxicology; Postgraduate Medicine; Primary Care Companion; Primary Psychiatry; Progress in Neuro-Psychopharmacology & Biological Psychiatry; Psychiatry Research; Psychological Medicine; Psychoneuroendocrinology; Psychopharmacology; The Psychiatric Times; Trends in Neurosciences; World Journal of Biological Psychiatry. Reviewer, Practice Parameters for the Assessment and Treatment of Children and Adolescents with Obsessive- Compulsive Disorder, American Academy of Child and Adolescent Psychiatry, 1997. Reviewer, Practice Guideline for the Treatment of Patients with Bipolar Disorder (Revision), American Psychiatric Association, 2001. Reviewer, Practice Guideline for the Treatment of Patients with Major Depressive Disorder (Third Ed.), American Psychiatric Association, 2010. Contributing editor, Yale Psychiatry, Yale Univ. Dept. of Psychiatry, 1991-1996. Editorial board, Journal of Depressive Disorders: Index & Reviews, 1996-1998. Editorial advisory board, In Progress, Brown Univ. Dept. of Psychiatry and Human Behavior, 1998-. Editorial advisory board, Psychopharmacology, 2000-2006. Acting field editor, Psychopharmacology, 2002. Principal editor (clinical psychopharmacology, North and South America), Psychopharmacology, 2006-. Guest editor, Biological Psychiatry, 2001-2002. Editor, Brown University Psychopharmacology Update, 2002-. Editorial advisory board, The Open Neuropsychopharmacology Journal, 2008-. Editorial advisory board, Drug, Healthcare and Patient Safety, 2008-. Editorial advisory board, Nutrition and Dietary Supplements, 2009-. Editorial consultant – Grune & Stratton, W.B. Saunders Company, Philadelphia, PA, 1988; W.H. Freeman and Co., New York, NY, 1990; Williams & Wilkins, Baltimore, MD, 1990-91; Oxford University Press, New York, NY, 2007; Cambridge University Press, New York, NY, 2009. Consultant (member, Expert Advisory Panel), Office of Scientific Integrity, National Institutes of Health, 1990- 1992.
3
Lawrence H. Price, MD
Special Review Consultant, Clinical and Behavioral Special Review Committee, National Institute on Drug Abuse, 1994-95. Special Review Consultant, Treatment Research Special Review Committee, National Institute on Drug Abuse, 1994. Special Review Consultant, General Clinical Research Center Review Committee Site Visit Team, National Center for Research Resources, 1996. Special Review Consultant (member, Special Emphasis Panel), Treatment Assessment Review Committee, National Institute of Mental Health, 1997. Special Review Consultant (member, Special Emphasis Panel), Health Behavior and Prevention Review Committee, National Institute of Mental Health, 1997. Special Review Consultant (member, Special Emphasis Panel), Medication Development Centers, National Institute on Drug Abuse, 1999. Special Review Consultant (member, Special Emphasis Panel); Integrative, Functional and Cognitive Neuroscience 1 (IFCN-1) IRG; Center for Scientific Review; National Institutes of Health, 2000. Special Review Consultant (member, Special Emphasis Panel); Interventions Research Review Committee (ZMH1- NRB-G-03); National Institute of Mental Health, 2002. Member, Merit Review Subcommittee for Mental Health and Behavioral Sciences, Medical Research Service, Dept of Veteran Affairs, 2000-2003. Special Review Consultant (member, Special Emphasis Panel); ZAA1 BB 12; National Institute on Alcohol Abuse and Alcoholism, 2004. Special Review Consultant (member, Special Emphasis Panel); ZAA1 EE 02; National Institute on Alcohol Abuse and Alcoholism, 2004. Special Review Consultant (member, Special Emphasis Panel); ZMH1 ERB-I; National Institute of Mental Health, 2008-. Member, Scientific Advisory Board, Obsessive Compulsive Foundation, 1994-1998. Member, Expert Consensus Panel on Obsessive Compulsive Disorder, Expert Consensus Consortium, 1996. Member, Scientific Advisory Board, Anxiety Disorders Association of America, 1997-1999. Member, Scientific Advisory Board, National Depressive and Manic-Depressive Association, 1999-2002. Member, Expert Consensus Panel on Guidelines for Antidepressant Medication in Primary Care, Expert Consensus Consortium, 1999. Adviser, DSM-IV Text Revision Work Group (Mood Disorders), Committee on Psychiatric Diagnosis and Assessment, Office of Research, American Psychiatric Association, 1999. Committees – Relationships with Advocacy Groups, ACNP, 1996-98; Oral Research Review, ADAA, 1998; Ad Hoc Faculty Promotion, Harvard Medical School, 1998; Genetics Advisory Conference Planning, Dept. of Health, State of RI, 2004-05; Education and Training, ACNP, 2012-2014. Data Safety Monitoring Boards – “Brief intervention to reduce drinking among batterers,” G. Stuart (P.I.), NIAAA (spons.), 2003-; “Brief intervention to reduce drinking among batterers and intimate partner violence in women,” G. Stuart (P.I.), NIAAA (spons.), 2007-; “Ketamine as a rapid treatment in post-traumatic stress disorder,” D. Charney (P.I), DOD (spons.), 2009-; “Intravenous ketamine for treatment-resistant bipolar depression,” J. Murrough (P.I), Mt. Sinai Schl Med, NY (spons.), 2009-11; "Continuation intravenous ketamine for major depressive disorder,” J. Murrough (P.I), Mt. Sinai Schl Med, NY (spons.), 2010-; "Use of ketamine anesthesia to enhance efficacy and tolerability of ECT,” J. Murrough (P.I), Mt. Sinai Schl Med, NY (spons.), 2010-11; “Optimization of IV ketamine for treatment resistant major depression,” J. Murrough (P.I), Mt. Sinai Schl Med, NY (spons.), 2010-11; “Intranasal (IN) ketamine for treatment resistant depression,” J. Murrough (P.I), Mt. Sinai Schl Med, NY (spons.), 2012-; “Investigating rapid anti-suicidal ideation effects of intravenous (IV) ketamine for hospitalized depression,” J. Murrough (P.I), American Foundation for Suicide Prevention (spons.), 2012-; “Intravenous (IV) ketamine in treatment-resistant obsessive-compulsive disorder (OCD),” W. Goodman (P.I), Mt. Sinai Schl Med, NY (spons.), 2012-; "RCT of hatha yoga for persistent depression" (chair), L. Uebelacker (P.I.), NINR (spons.), 2011-. Mentor, Lilly Psychiatric Research Fellowship, 1990. Mentor, NARSAD Young Investigator Awards, 1991, 1994-95, 1997-98, 2000, 2002-03. Mentor, ACNP Minority Mini-Fellowship, 1997. Mentor, NIMH K08 Award, 1999-2003. Mentor, APA/Lilly Resident Research Award, 2000, 2009. Mentor, Pfizer/Society for Women's Health Research Scholars Grant for Faculty Development in Women's Health, 2002-2003.
4
Lawrence H. Price, MD
Mentor, Janssen Pharmaceutica Faculty Development Award in Psychopharmacology, 2003. Co-mentor, NIMH K23 Award, 2003-2008. Mentor, NIMH K23 Award, 2004-2009. Co-mentor, NIDA K08 Award, 2004-2009. Co-mentor, NIMH K23 Award, 2007-2012.
HOSPITAL COMMITTEES
Norwalk Hosp.: Pharmacy and Therapeutics, 1978-79. Connecticut Mental Health Center: Safety, 1984-88; Quality Assurance, 1984-89; Pharmacy and Therapeutics (chair), 1984-96; Credentials, 1986-96; Peer Review, 1988-90; Accreditation, 1988-89; Clinical Chiefs, 1988-96; Founding President, Medical Staff, 1989-1990; Executive Committee of the Medical Staff, 1989-96; Clinical Planning, 1989-90; Treatment Research Unit Planning, 1989-90, 1992; Pharmacy Cost Reduction,1990-91; Ambulatory Services/Quality Assurance, 1990-92; Clinical Reorganization/Coordinating, 1991-93; Director's Research, 1993-96. Butler Hosp.: Research (chair), 1996-2001; Institutional Review Board (chair), 1996-; Hospital Operations/Associate Medical Directors, 1996-; Senior Management, 1996-; GFT Research Funds (chair), 1996- 2001; Continuing Medical Education, 1996-; Executive Management, 1996-; Board of Trustees, 1997-2011; Library, 1997-; Physician's Subcommittee, Improvement of Organizational Performance, 1997-99; Medical Matters, 1997-; Improvement of Organizational Performance, 1997-99; Budget, 1997-; Clinical Leadership (chair), 1997-; Unit Chiefs/Nurse Managers (chair), 1997-2003; Care of the Patient (co-chair), 1997-99; Community Bed Coordinating (chair), 1997-2002; Education and Research, 1997-2002; Leadership, Improvement, and Planning, 1999-2002; Environment of Care, 2000-2002; Health Education and Wellness, 2001-02; Search, Vice-President for Patient Care Services/Chief Nurse Executive (chair), 2002-03; Leadership Work Group, 2002-07; Medication Occurrence Review, 2002-08; MHRH Physicians Group, 2003-05; Research Strategic Planning (chair), 2004-; Utilization Review (chair, 2004-09), 2004-; Medicare Utilization, 2004-05; Academic (Board of Trustees), 2005-11; MHRH/Medicare Utilization, 2005-07; CNErgy Butler Executive, 2005- 08; Academic Compensation/Academic Planning, 2007-; Information Therapy, 2008-09; Medical Administration, 2009-; Foundation Board of Trustees, 2011-; Foundation Community Development, 2012-. Care New England: Medical and Health Professionals Education and Research Work Group, 1997-98; Physician Advisory, 2007-09; Academic and Research IS Steering, 2009-11; Senior Management, 2011-; Academic Council, 2012-.
UNIVERSITY COMMITTEES
Yale Dept. of Psychiatry: Faculty interviewer for Residency Selection Committee, 1982-96; Residency Education, 1985-87; Research Forum Program, 1985-96; Ad hoc Curriculum, 1986-87; Continuing Medical Education, 1987- 89; Forum Program, 1988-96; PGY-2 Curriculum, 1991-96; Clinical Programs (chair, Subcommittee on Mood Disorders), 1993-94; Mood Disorders Clinical Research (co-chair), 1993-96; Chairman's Residency Program Review, 1995. Yale Schl. of Medicine: Funds and Fellowships, 1991-92; General Clinical Research Center Medical Advisory, 1995-96. Brown Dept. of Psychiatry and Human Behavior: Executive Committee on Research, 1996-2009; Policy Management Advisory, 1996-2009; Residency Curriculum, 1996-2002; Faculty interviewer for Residency Selection Committee, 1996-; Reappointments and Promotions, 1996-; Graduate Medical Education Policy, 1999-; Research Oversight, 2005-06; Leadership Council, 2009-; Department of Psychiatry Advisory, 2009-; Resident Progressions, 2011-. Warren Alpert Med. Schl. of Brown Univ.: Search, Medicine Chair, 2008-10; Graduate Medical Education, 2009-; Norman Prince Neurosciences Institute Steering, 2011-. Brown Univ.: Conflict of Interest Review Board, 2009-; Conflict of Interest Oversight Subcommittee (for J. Fallon) (chair), 2010-.
5
Lawrence H. Price, MD
MEMBERSHIP IN SOCIETIES
Member – American Psychiatric Association, 1983-1987, 1996-; Connecticut Psychiatric Society, 1983-1987; Society for Neuroscience, 1985-; International Brain Research Organization, 1985-; American Association for the Advancement of Science, 1989-; American College of Neuropsychopharmacology, 1990-; Rhode Island Psychiatric Society, 1996-; Anxiety Disorders Association of America, 1998-2000; National Depressive and Manic-Depressive Association, 1999-2002.
PUBLICATIONS (peer-reviewed)
Original Articles
1. Atkinson JW, Bongort K, Price LH. Explorations using computer simulation to comprehend thematic apperceptive measurement of motivation. Motiv and Emot 1:1-27, 1977. 2. Leigh H, Price L, Ciarcia J, Mirassou M. DSM III and consultation-liaison psychiatry: Toward a comprehensive medical model of the patient. Gen Hosp Psychiatry 4:283-289, 1982. 3. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 140:318-322, 1983. PMID 6131612 4. Price LH, Nelson JC, Waltrip RW. Desipramine-associated hepatitis. J Clin Psychopharmacol 3:243-246, 1983. 5. Price LH, Nelson JC, Charney DS, Quinlan DM. Family history in delusional depression. J Affect Disord 6:109-114, 1984. 6. Price LH, Nelson JC, Charney DS, Quinlan DM. The clinical utility of family history for the diagnosis of melancholia. J Nerv Ment Dis 172:5-11, 1984. 7. Price LH, Nelson JC, Jatlow PI. Effects of desipramine on clinical liver function tests. Am J Psychiatry 141:798- 800, 1984. 8. Price LH, Charney DS, Heninger GR. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 141:1267-1268, 1984. 9. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 142:619-623, 1985. PMID 3920923 10. Rubin AL, Price LH, Charney DS, Heninger GR. Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatr Res 15:5-15, 1985. 11. Rubin AL, Charney DS, Price LH, Heninger GR. Rapid improvement of delusional depression following two drug- induced seizures. J Clin Psychiatry 46:146-147, 1985. 12. Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 37:809-818, 1985. 13. Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology 89:38-44, 1986. 14. Mazure C, Nelson JC, Price LH. Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 43:451-456, 1986. 15. Innis RB, Bunney BS, Charney DS, Price LH, Glazer WM, Sternberg DE, Rubin AL, Heninger GR. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatr Res 18:1-7, 1986. 16. Price LH, Charney DS, Rubin AL, Heninger GR. Alpha-2 adrenergic receptor function in depression: The cortisol response to yohimbine. Arch Gen Psychiatry 43:849-858, 1986. PMID 3019271 17. Goodman WK, Charney DS, Price LH, Woods SW, Heninger GR. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: Report of three cases. Am J Psychiatry 143:900-903, 1986. 18. Nelson JC, Price LH, Jatlow PI. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 143:1151-1154, 1986. 19. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143:1387-1392, 1986. PMID 3096155 20. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression: Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 43:1155-1161, 1986. PMID 3022664 21. Price LH, Goodman WK, Charney DS, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059-1061, 1987.
6
Lawrence H. Price, MD
22. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects. Psychopharmacology 92:431-437, 1987. PMID 2442788 23. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive compulsive disorder: A comparison of the effects of tryptophan and MCPP in patients and healthy subjects. Arch Gen Psychiatry 45:177-185, 1988. 24. Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Res 24:165-175, 1988. 25. Delgado PL, Price LH, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15:55-60, 1988. 26. Heninger GR, Charney DS, Price LH. Alpha-2-adrenergic receptor function in depression: The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch Gen Psychiatry 45:718-726, 1988. 27. Murburg MM, Price LH, Jalali B. Huntington's disease: Therapeutic strategies. Fam Syst Med 6:290-303, 1988. 28. Price LH, Delgado PL, Charney DS, Heninger GR. Sequence of drug administration in lithium augmentation: A case study. J Clin Psychiatry 49:161-162, 1988. 29. Salloway S, Price LH, Charney DS, Shapiro M. Multiple sclerosis presenting as major depression: A diagnosis suggested by MRI scan but not CT scan. J Clin Psychiatry 49:364-366, 1988. 30. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive compulsive disorder: A double-blind comparison with placebo. Arch Gen Psychiatry 46:36-44, 1989. 31. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium treatment and serotonergic function: Neuroendocrine, behavioral, and physiologic responses to intravenous L-tryptophan in affective disorder patients. Arch Gen Psychiatry 46:13-19, 1989. 32. Price LH, Ricaurte GA, Krystal JH, Heninger GR. Neuroendocrine and mood responses to I.V. L-tryptophan in 3,4- methylenedioxymethamphetamine (MDMA) users: Preliminary findings. Arch Gen Psychiatry 46:20-22, 1989. 33. Price LH, Charney DS, Delgado PL, Anderson GM, Heninger GR. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625-631, 1989. 34. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman R, Hill C, Heninger GR, Charney DS. The Yale- Brown Obsessive Compulsive Scale (Y-BOCS): I. Development, use, and reliability. Arch Gen Psychiatry 46:1006- 1011. 1989. 35. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado PL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): II. Validity. Arch Gen Psychiatry 46:1012-1016. 1989. 36. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR. Neuroendocrine and behavioral effects of dietary tryptophan depletion in healthy subjects. Life Sci 45:2323-2332, 1989. 37. Seibyl JP, Krystal JH, Goodman WK, Price LH. Obsessive-compulsive symptoms in a patient with a right frontal lobe lesion: Response to lithium augmentation of tranylcypromine. Neuropsychiatry, Neuropsychol, and Behav Neurol 1:295-299. 1989. 38. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: Implications for the serotonin hypothesis of depression. Psychopharmacology 100:3-12,1990. 39. Nierenberg AA, Price LH, Charney DS, Heninger GR. After lithium augmentation: A retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 18:167-175, 1990. 40. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan C, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Dependence 25:73-78,1990. 41. McDougle CJ, GoodmanWK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147:652-654, 1990. 42. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418, 1990. 43. GoodmanWK, Price LH, Delgado PL, Palumbo J, Krystal JH, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47:577-585, 1990. 44. Price LH, Charney DS, Delgado PL, Heninger GR. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 10:312-317, 1990. 45. McDougle CJ, Price LH, Goodman, WK. Fluvoxamine treatment of autistic disorder and obsessive compulsive disorder: A case report. J Autism Dev Disorders 20(4):537-543, 1990. 46. Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Brit J Psychiatry 157:762-765, 1990.
7
Lawrence H. Price, MD
47. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: Lack of efficacy. J Clin Psychopharmacol 11:175-184, 1991. 48. Price LH, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: Neuroendocrine and mood responses to intravenous L-tryptophan in DSM-III-R depressive subtypes and healthy controls. Am J Psychiatry 148:1518-1525, 1991. 49. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 38:227-236, 1991. 50. Satel SL, Price LH, Palumbo JM, McDougle CJ, Krystal JH, Gawin F, Charney DS, Heninger GR, Kleber HD. The clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. Am J Psychiatry 148:1712-1716, 1991. 51. McCance-Katz EF, Price LH, Charney DS, Heninger GR. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 108:93-97, 1992. 52. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: Preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry, 31(4):746-750, 1992. 53. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18:331-341, 1992. 54. Krystal JH, McDougle CJ, Woods SW, Price LH, Heninger GR, Charney DS. Dose-response relationship for oral idazoxan effects in healthy human subjects: Comparison with oral yohimbine. Psychopharmacology 108:313-319, 1992. 55. Krystal JH, McDougle CJ, Kosten TR, Price LH, Aghajanian GK, Charney DS. Baclofen-assisted detoxification from opiates: A pilot study. J Subst Abuse Treatment 9:139-142, 1992. 56. McDougle CJ, Price LH, Palumbo JM, Kosten TR, Heninger GR, Kleber HD. Dopaminergic responsivity during cocaine abstinence. Psychiatry Res 43:77-85,1992. 57. McCance-Katz EF, Marek KL, Price LH. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42:1813-1814, 1992. 58. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: Implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 109:2-11, 1992. 59. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, Sass KJ, Elsworth JD, Kier L, Makuch R, Hoffer PB, Redmond DE. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 327:1541-1548, 1992. 60. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz EF, Heninger GR, Price LH. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 150:647-649, 1993. 61. McCance-Katz EF, Price LH, McDougle CJ, Kosten TR, Black JE, Jatlow PI. Concurrent cocaine-ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology 111:39-46, 1993. 62. McDougle CJ, Naylor ST, Goodman WK, Volkmar FR, Cohen DJ, Price LH. Acute tryptohan depletion in autistic disorder: A controlled case study. Biol Psychiatry 33:547-550, 1993. 63. Zimmerman RC, McDougle CJ, Schumacher M, Olcese J, Mason JW, Heninger GR, Price LH. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. J Clin Endocr Metab 76:1160-1164, 1993. 64. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 50:624-635, 1993. 65. Rosen MI, Pearsall HR, Price LH, McDougle CJ, Woods SW, Kosten TR. Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone-maintained patients. Am J Addictions 2(2):165-168, 1993. 66. Rosen MI, Pearsall HR, McDougle CJ, Price LH, Woods SW, Kosten TR. Effects of acute buprenorphine on responses to intranasal cocaine: A pilot study. Am J Drug Alcohol Abuse 19(4):451-464, 1993. 67. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13:354-358, 1993. 68. Calvocoressi L, McDougle CJ, Wasylink S, Goodman WK, Price LH. Hospital treatment of patients with severe obsessive compulsive disorder. Hosp Community Psychiatry 44:1150-1154, 1993.
8
Lawrence H. Price, MD
69. Zimmermann RC, McDougle CJ, Schumacher M, Olcese J, Heninger GR, Price LH. Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology 18:567- 578, 1993. 70. Wexler BE, Levenson L, Warrenburg S, Price LH. Decreased perceptual sensitivity to emotion-evoking stimuli in depression. Psychiatry Res 51:127-138, 1994. 71. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine- refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308,1994. 72. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, Price LH. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51:309-317,1994. 73. Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarsky BK, Leckman JF, Price LH. Obsessive compulsive disorder with and without a chronic tic disorder: A comparison of symptoms in 70 patients. Br J Psychiatry 164:469- 473, 1994. 74. Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Dependence 35:141-149,1994. 75. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 331:591-598, 1994. 76. McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH. Noradrenergic dysregulation during cocaine abstinence in cocaine addicts: biochemical, behavioral, and cardiovascular correlates. Arch Gen Psychiatry 51:713-719, 1994. 77. Leckman JF, Goodman WK, North W, Chappell PB, Price LH, Pauls DL, Anderson GM, Riddle MA, McSwiggan- Hardin M, McDougle CJ, Barr LC, Cohen DJ. Elevated cerebrospinal fluid levels of oxytocin in obsessive- compulsive disorder patients: Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 51:782-792, 1994. 78. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 151:1626-1630, 1994. 79. Epperson CN, McDougle CJ, Anand A, Marek GJ, Naylor ST, Volkmar FR, Cohen DJ, Price LH. Lithium augmentation of fluvoxamine in autistic disorder: A case report. J Child Adolesc Psychopharmacology 4:201-207, 1994. 80. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS. Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874, 1994. 81. Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, Anderson GM, Riddle MA, McDougle CJ, Barr LJ, Cohen DJ. The role of central oxytocin in obsessive compulsive disorder and related behavior. Psychoneuroendocrinology 19:723-749, 1994. 82. Goddard AW, Sholomskas DE, Walton KE, Augeri FM, Charney DS, Heninger GR, Goodman WK, Price LH. Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36:775-777, 1994. 83. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, Van Dyck CC, Price LH, Zubal G, Hofer PB, Charney DS. Opiate dependence and withdrawal: Preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 21:47-63, 1995. 84. Anand A, Malison R, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: A case report. Biol Psychiatry 37:338-340, 1995. 85. Calvocoressi L, Lewis B, Kennedy M, Goodman WK, Trufan SJ, McDougle CJ, Price LH. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry 152:441-443, 1995. 86. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, Cohen DJ, Price LH. CSF biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12:73-86, 1995. 87. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152:772-777, 1995. 88. McDougle CJ, Krystal JH, Price LH, Heninger GR, Charney DS. Noradrenergic response to acute ethanol administration in healthy subjects: Comparison with intravenous yohimbine. Psychopharmacology 118:127-135, 1995.
9
Lawrence H. Price, MD
89. Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR. Behavioral, physiological, and pharmacological interactions of cocaine and disulfiram in humans. Biol Psychiatry 37:560-563, 1995. 90. Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH. Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology 119:179-185, 1995. 91. McCance EF, Price LH, Kosten TR, Jatlow PI. Cocaethylene: Pharmacology, physiology, and behavioral effects in humans. J Pharmacol Exp Ther 274:215-223,1995. 92. Goddard AW, Charney DS, Germine M, Woods SW, Heninger GR, Krystal JH, Goodman WK, Price LH. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry 38:74-85, 1995. 93. Malison RT, McDougle CJ, van Dyck C, Scahill L, Baldwin RM, Seibyl JP, Price LH, Leckman JF, Innis RB. [123I]b-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 152:1359-1361, 1995. 94. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR. M- chlorophenylpiperazine in patients with obsessive compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 38:138-149, 1995. 95. Price LH, Spencer DD, Marek KL, Robbins RJ, Leranth C, Farhi A, Naftolin F, Roth RH, Bunney BS, Hoffer PB, Makuch R, Redmond DE. Psychiatric status after human fetal mesencephalic transplantation in Parkinson's disease. Biol Psychiatry 38:498-505, 1995. 96. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH, Price LH, Bunney BS, Elsworth JD, Hoffer PB, Redmond DE, Spencer DD. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurology 52:680-686, 1995. 97. McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: Three cases. J Clin Psychiatry 56:526-528, 1995. 98. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152:1812-1814, 1995. 99. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacology 5:273-282, 1995. 100. Cappiello A, McDougle CJ, Malison RT, Heninger GR, Price LH. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biol Psychiatry 38:765-767, 1995. 101. Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, Price LH, Kosten TR, Innis RB. Euphorigenic doses of cocaine reduce [123I]b-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122:358-362, 1995. 102. Kosten TR, Kosten TA, McDougle CJ, Hameedi FA, Rosen MI, Oliveto A, Price LH. Gender differences in response to intranasal cocaine administration. Biol Psychiatry 39:147-148,1996. 103. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive compulsive disorder. Biol Psychiatry 40:547-549, 1996. 104. Cappiello A, Malison RT, McDougle CJ, Vegso S, Charney DS, Heninger GR, Price LH. Seasonal variation in neuroendocrine and mood responses to i.v. L-tryptophan in depressed patients and healthy subjects. Neuropsychopharmacology 15:475-483, 1996. 105. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autism. Arch Gen Psychiatry 53:993-1000,1996. 106. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996. 107. Rasmusson AM, Anderson GM, Lynch KA, McSwiggan-Hardin M, Scahill LD, Mazure CM, Goodman WK, Price LH, Cohen DJ, Leckman JF. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry 41:117-121, 1997. 108. Kirwin PD, Anderson GM, Chappell PB, Saberski L, Leckman JF, Geracioti TD, Heninger GR, Price LH, McDougle CJ. Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human females. Life Sci 60:899-907, 1997. 109. Barr LC, Heninger GR, Goodman W, Charney DS, Price LH. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41:949-954, 1997. 110. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54:364-374, 1997.
10
Lawrence H. Price, MD
111. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693, 1997. 112. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295, 1997. 113. Price LH, Cappiello A, Malison RT, McDougle CJ, Pelton GH, Schöllnhammer G, Heninger GR. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects. Neuropsychopharmacology 17:246-257, 1997. 114. Price LH, Malison RT, McDougle CJ, McCance-Katz EF, Owen K, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 17:342-350, 1997. 115. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. J Child Adolesc Psychopharmacology 7:109-121, 1997. 116. Gelernter J, van Dyck C, van Kammen DP, Malison R, Price LH, Cubells J, Berman R, Charney DS, Heninger G. Ciliary neurotrophic factor null allele frequency in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet (Neuropsych Genet) 74:497-500, 1997. 117. Cappiello A, Sernyak M, Malison RT, McDougle CJ, Heninger GR, Price LH. Effects of acute tryptophan depletion in lithium-remitted manic patients: Preliminary findings. Biol Psychiatry 42:1076-1078, 1997. 118. Calvocoressi L, Libman D, Vegso S, McDougle CJ, Price LH. Global functioning in obsessive-compulsive disorder: A preliminary comparison with schizophrenia and major depression. Psychiatr Serv 49:379-381, 1998. 119. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J Clin Psychopharmacology 18:62-66, 1998. 120. Narayan M, Anderson G, Cellar J, Malison RT, Price LH, Nelson JC. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacology 18:67-71, 1998. 121. Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion. Biol Psychiatry 43:339-347, 1998. 122. Carpenter LL, Anderson GM, Pelton GH, Gudin JA, Kirwin PD, Price LH, Heninger GR, McDougle CJ. Tryptophan depletion during continuous CSF sampling via indwelling lumbar catheter in healthy human subjects. Neuropsychopharmacology 19:26-35, 1998. 123. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TE, Innis RB. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]b- CIT SPECT. Am J Psychiatry 155:832-834, 1998. 124. McDougle CJ, Epperson CN, Price LH, Gelernter JE. Evidence for linkage disequilibrium between serotonin transporter protein (SLC6A4) and obsessive compulsive disorder. Molec Psychiatry 3:270-273, 1998. 125. Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW. Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Dependence 50:187-195, 1998. 126. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633- 641, 1998. 127. Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL, Krystal JH, Price LH. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacology 18:248-251, 1998. 128. Cubells JF, van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelernter J. Dopamine β-hydroxylase: Two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genetics 102:533-540, 1998. 129. Cappiello A, McDougle CJ, Delgado PL, Malison RT, Jatlow P, Charney DS, Heninger GR, Price LH. Lithium+desipramine vs. desipramine alone in the treatment of severe major depression: A preliminary study. Int Clin Psychopharmacology 13:191-198, 1998. 130. Malison RT, Price LH, Berman R, van Dyck CJ, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44:1090-1098, 1998. 131. Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology 137(4):321-325, 1998. 132. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60:45-49, 1999.
11
Lawrence H. Price, MD
133. McDougle CJ, Barr LC, Goodman WK, Price LH. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24:1-24, 1999. 134. Carpenter LL, Jocic Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11:81-86, 1999. 135. Bruder GE, Wexler BE, Stewart JE, Price LH, Quitkin FM. Perceptual asymmetry differences between major depression with or without a comorbid anxiety disorder: A dichotic listening study. J Abnorm Psychology 108:233- 239, 1999. 136. Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, Price LH. Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 85:225-240, 1999. 137. Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ. Risperidone addition in serotonin uptake inhibitor- resistant trichotillomania: Three cases. J Child Adolesc Psychopharmacology 9:43-49. 1999. 138. Longhurst JG, Carpenter LL, Epperson CN, Price LH, McDougle CJ. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 46:573-576, 1999. 139. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, Heninger GR, Price LH. Limited efficacy of ketoconazole in treatment refractory major depression. J Clin Psychopharmacology 19:466-470, 1999. 140. Calvocoressi L, Mazure C, Kasl S, Skolnick J, Fisk D, Vegso S, Van Noppen B, Price LH. Family accommodation of obsessive-compulsive symptoms: Instrument development and assessment of family behavior. J Nerv Ment Dis 187:636-642, 1999. 141. Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, Price LH, Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine b-hydroxylase activity, also associates with cocaine-induced paranoia. Molec Psychiatry 5:56-63, 2000. 142. Desan PH, Oren DA, Malison R, Price LH, Rosenbaum J, Smoller J, Charney DS, Gelernter J. Genetic polymorphism at the CLOCK gene locus and major depression. Am J Med Genet (Neuropsychiatr Genet) 96:418-421, 2000. 143. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive compulsive disorder. Arch Gen Psychiatry 57:794-801, 2000. 144. Gagne GG Jr, Furman MJ, Carpenter LL, Price LH. The efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 157:1960-1965, 2000. PMID 11097961 145. Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH. Adjunctive gabapentin in treatment-resistant depression: A retrospective chart review. J Aff Disord 63:243-247, 2001. 146. Eisen JL, Rasmussen SA, Phillips KA, Price LH, Davidson J, Lydiard RB, Ninan P, Piggott T. Insight and treatment outcome in obsessive compulsive disorder. Compr Psychiatry 42:494-497, 2001. 147. Eisen JL, Leonard H, Swedo S, Price LH, Zabriskie JB, Chiang SY, Karitani M, Rasmussen SA. Antibody D8/17 identification of B cells in adults with obsessive compulsive disorder. Psychiatry Res 104:221-225, 2001. 148. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183-188, 2002. PMID 11822997 149. Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J. Genotype-controlled analysis of plasma dopamine ß–hydroxylase activity in psychotic unipolar depression. Biol Psychiatry 51:358-364, 2002. 150. Carpenter LL, Leon Z, Yasmin S, Price LH. Do obese depressed patients respond to topiramate? A retrospective review. J Aff Disord 69:251-255, 2002. 151. Lappalainen J, Kranzler HR, Malison R, Price LH, Van Dyck C, Rosenheck RA, Cramer J, Southwick S, Charney D, Krystal J, Gelernter J. A functional neuropeptide Y Leu7Pro polymorphism is associated with alcohol dependence in a large population sample from the U.S. Arch Gen Psychiatry 59:825-831, 2002. 152. Carpenter LL, Heninger GR, McDougle CJ, RT, Tyrka AR, Epperson CN, Price LH. Cerebrospinal fluid interleukin (IL)-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res 112:257-262. 2002. 153. Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28(2):339-347, 2003. 154. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2):402-412, 2003. 155. Giambalvo CT, Price LH. Effects of fenfluramine and antidepressants on protein kinase C activity in rat cortical synaptoneurosomes. Synapse 50:212-222, 2003.
12
Lawrence H. Price, MD
156. de Mello AAF, de Mello MF, Carpenter LL, Price LH. Update on stress and depression: The role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev Bras Psiquiatr 25(4):231-238, 2003. 157. Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet (Neuropsychiatr Genet) 124B(1):81-86, 2004. 158. Nelson JC, Mazure CM, Bowers MB, Jr, Jatlow PI, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 55:296-300, 2004. PMID 14744472 159. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Aff Disord 79:285-289, 2004. 160. Carpenter LL, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Cerebrospinal fluid corticotrophin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 29(4):777-784, 2004. 161. Najjar F, Welch C, Grapentine WL, Sachs H, Siniscalchi J, Price LH. Trends in psychotropic drug use in a child psychiatric hospital from 1991 through 1998. J Child Adol Psychopharmacology 14(1):87-93, 2004. 162. Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry 56(6):418-426, 2004. 163. Tyrka AR, Carpenter LL, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Strong DR, Price LH. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry 56(7):531-534, 2004. 164. Carpenter LL, Schecter JM, Underwood JA, Tyrka, AR, Price LH. Service expectations and clinical characteristics of patients receiving psychiatric emergency services. Psychiatr Serv 56(6):743-745, 2005. 165. Phillips KA, Grant JE, Siniscalchi JM, Stout R, Price LH. A retrospective follow-up study of body dysmorphic disorder. Compr Psychiatry 46(5):315-321, 2005. 166. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry 66(10):1234-1238, 2005. 167. Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 67:66-71, 2006. 168. Geracioti TD, Carpenter L, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163:637-643, 2006. 169. Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, Price LH, Southwick S, Yang BZ, Rasmussen A, Gelernter J. Brain derived neurotrophic factor (BDNF) genetic variants and Alzheimer’s disease, affective disorders, posttraumatic stress disorder, schizophrenia and substance dependence. Am J Med Genet B Neuropsychiatr Genet 141B:387-393, 2006. 170. Tyrka AR, Mello AF, Mello MF, Gagne GG, Grover KE, Anderson GM, Price LH, Carpenter LL. Temperament and hypothalamic-pituitary-adrenal axis function in healthy adults. Psychoneuroendocrinology 31(9):1036-1045, 2006. 171. Tyrka AR, Wier LM, Anderson GM, Wilkinson CW, Price LH, Carpenter LL. Temperament and response to the Trier Social Stress Test. Acta Psychiatr Scand 115:395-402, 2007. 172. Grover KE, Carpenter LL, Price LH, Gagne GG, Mello AF, Mello MF, Tyrka AR. The relationship between childhood abuse and adult personality disorder symptoms. J Personal Disord 21(4):442-447, 2007. 173. Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH. Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. Biol Psychiatry 62(10):1080-1087, 2007. 174. Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Kinkead B, Owens MJ, Nemeroff CB. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res 157:123-129, 2008. 175. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical neuroleptics: A review of the current literature. J Psychiatr Pract 34(1):34-44, 2008. 176. Kelly MM, Tyrka AR, Anderson GA, Price LH, Carpenter LL. Sex differences in emotional and physiological responses to the Trier Social Stress Test. J Behav Ther Exp Psychiatry 39(1):87-98, 2008. 177. Rikhye K, Tyrka AR, Kelly MM, Gagne GG Jr, Mello AF, Mello MF, Price LH, Carpenter LL. Interplay between childhood maltreatment, parental bonding, and gender effects: Impact on quality of life. Child Abuse Negl 32:19-34, 2008.
13
Lawrence H. Price, MD
178. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Ann Clin Psychiatry 20(1):15-20, 2008. 179. Tyrka AR, Wier LM, Price LH, Rikhye K, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL. Cortisol and ACTH responses to the Dex/CRH test: Influence of temperament. Horm Behav 53(4):518-525, 2008. 180. Tyrka AR, Wier LM, Price LH, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry 63(12):1147-1154, 2008. 181. Abrantes AM, Strong DR, Lejuez CW, Kahler CW, Carpenter LL, Price LH, Niaura R, Brown RA. The role of negative affect in risk for early lapse among low distress tolerance smokers. Addict Behav 33:1394-1401, 2008. 182. Kelly MM, Tyrka AR, Price LH, Carpenter LL. Sex differences in the use of coping strategies: Predictors of anxiety and depressive symptoms. Depress Anxiety 25:839-846, 2008. 183. Price LH, Carpenter LL, Tyrka AR. Lithium augmentation for refractory depression: A critical reappraisal. Prim Psychiatry 25(11):35-42, 2008. 184. Tyrka AR, Wier L, Price LH, Ross NS, Carpenter LL. Childhood parental loss and adult psychopathology: Effects of loss characteristics and contextual factors. Int J Psychiatry Med 38(3):329-344, 2008. 185. Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 65(4):267-275, 2009. PMID 18842257 186. Tyrka AR, Wyche MC, Kelly MM, Price LH, Carpenter LL. Childhood maltreatment and adult personality disorder symptoms: Influence of maltreatment type. Psychiatry Res 165:281-287, 2009. 187. Brown, RA, Lejuez CW, Strong DR, Kahler CW, Zvolensky MJ, Carpenter LL, Niaura R, Price LH. A prospective examination of distress tolerance and early smoking lapse in adult self-quitters. Nicotine Tob Res 11(5):493-502, 2009. 188. Zuo L, Luo X, Listman JB, Kranzler HR, Wang S, Anton RF, Blumberg HP, Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, Price LH, Lappalainen J, Cramer J, Krystal JH, Gelernter J. Population admixture modulates risk for alcohol dependence. Hum Genet 125(5-6):605-613, 2009. 189. Carpenter LL, Tyrka AR, Ross NS, Anderson GM, Price LH. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. Biol Psychiatry 66(1):69-75, 2009. 190. Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH. Dex/CRH cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 34:1208-1213, 2009. PMID 19375869 191. Philip NS, Carpenter LL, Tyrka AR, Whiteley L, Price LH. Varenicline augmentation in depressed smokers: An 8- week, open-label study. J Clin Psychiatry 70(7):1026-1031, 2009. PMID 19323966 192. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson G, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: Effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 66(7):681-685, 2009. 193. Amin Z, Kanarek K, Krupitsky E, Walderhaug E, Ilomäki R, Blumberg H, Price LH, Bhagwagar Z, Carpenter LL, Tyrka AR, Magnusson A, Landrø NI, Zvartau E, Gelernter J, Epperson NE, Räsänen P, Siironen J, Lappalainen J. A sequencing-based survey of functional APAF1 alleles in a large sample of individuals with affective illness and population controls. Am J Med Genet B Neuropsychiatr Genet. 153B(1):332-335, 2009. 194. Tyrka AR, Price LH, Kao H-T, Porton B, Marsella SA, Carpenter LL. Childhood maltreatment and telomere shortening: Preliminary support for an effect of early stress on cellular aging. Biol Psychiatry 67(6):531-534, 2010. 195. Philip N, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: A re- examination for the modern era. Expert Opin Pharmacother 11(5):709-722, 2010. 196. Schoedl AF, Costa MCP, Mari JJ, Mello MF, Tyrka AR, Carpenter LL, Price LH. The clinical correlates of reported childhood sexual abuse: An association between age at trauma onset and severity of depression and PTSD in adults. J Child Sex Abuse 19(2):156-170, 2010. 197. Storch EA, Larson MJ, Price LH, Rasmussen SA, Murphy TK, Goodman WK. Psychometric analysis of the Yale- Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord 24(6):650-656, 2010. 198. Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale Second Edition. Psychol Assess 22(2):223-232, 2010. 199. Hitsman B, Shen B-J, Cohen RA, Morissette SB, Drobes DJ, Spring B, Schneider K, Evans DE, Gulliver SB, Kamholz BW, Price LH, Niaura R. Measuring smoking-related preoccupation and compulsive drive: Evaluation of the Obsessive Compulsive Smoking Scale. Psychopharmacology 211(4):377-387, 2010. 200. Philip N, Carpenter LL, Tyrka AR, Price LH. Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature. Psychopharmacology 212(1):1-12, 2010. PMID 20614106
14
Lawrence H. Price, MD
201. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 35(13):2617-2623, 2010. PMID: 20881945 202. Nugent NR, Tyrka AR, Carpenter LL, Price LH. Gene-environment interactions: Early life stress and risk for depressive and anxiety disorders. Psychopharmacology 214(1):175-196, 2011. PMID: 21225419 203. Carpenter LL, Shattuck TT, Tyrka AR, Geracioti TM, Price LH. Effect of childhood physical abuse on cortisol stress response. Psychopharmacology 214(1):367-375, 2011. PMID: 20838776 204. Cui D, Zhang H, Yang BZ, Listman JB, Li D, Price LH, Carpenter LL, Tyrka AR, Anton RF, Kranzler HR, Gelernter J. Variation in NGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet 56(4):401-412, 2011. PMID: 21294249 205. Carpenter LL, Tyrka AR, Lee JK, Tracy AP, Wilkinson CW, Price LH. A placebo-controlled study of sertraline’s effect on cortisol response to dexamethasone/corticotropin-releasing hormone test in healthy adults. Psychopharmacology. 218(2):371-379, 2011. PMID: 21617914. 206. McGuire JF, Storch EA, Lewin AB, Price LH, Rasmussen SA, Goodman WK. The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 53(2):187-194, 2012. PMID: 21550030 207. Tyrka AR, Price LH, Marsit C, Walters C, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: Preliminary findings in healthy adults. PLoS One. 7(1):e30148. Epub Jan 25, 2012. PMID: 22295073 208. Philip NS, Carpenter LL, Tyrka AR, Price LH. The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal. 2012:104105, 7 pages. Epub Apr 24, 2012. PMID: 22619570 209. Tyrka AR, Walters OC, Price LH, Anderson GM, Carpenter LL. Altered response to neuroendocrine challenge linked to indices of the metabolic syndrome in healthy adults. Horm Metab Res. 44(7):543-549, 2012. PMID: 22549400 210. Carpenter LL, Gawuga CE, Tyrka AR, Price LH. C-reactive protein, early life stress, and wellbeing in healthy adults. Acta Psychiatr Scand. Epub ahead of print June 12, 2012. PMID: 22681496. 211. Price LH, Kao H-T, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and early-life stress: An overview. Biol Psychiatry. In press. 212. Philip NS, Sweet LH, Tyrka AR, Price LH, Bloom RF, Carpenter LL. Decreased default network connectivity is associated with early life stress in medication-free healthy adults. In review. 213. Hitsman B, Hogarth L, Tseng L-J, Teige JC, Shadel WG, Dibendetti DB, Danto S, Lee TC, Price LH, Niaura R. Dissociable effect of acute varenicline on tonic versus cue-provoked cigarette craving in non-treatment-motivated heavy smokers. In review. 214. Case BG, Bertollo DN, Laska EM, Siegel CE, Wanderling JA, Price LH, Olfson M. Declining use of electroconvulsive therapy in US hospitals. In review. 215. Carpenter LL, Gawuga CE, Tyrka AR, Price LH. Predictors of IL-6 response to acute psychosocial stress. In preparation. 216. Brown RA, Abrantes AM, Niaura R, Strong DR, Kahler CW, Miller IW, Price LH. Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. In preparation.
OTHER PUBLICATIONS (non-peer-reviewed)
Reviews, Chapters, Books:
1. Atkinson JW, Bongort K, Price LH. Explorations using computer stimulation to comprehend thematic apperceptive measurement of motivation. Chapter in: Personality, Motivation and Action: Selected Papers, Atkinson JW, Praeger Publishers, New York, pp 311-337, 1983. 2. Price LH. Distinguishing clinical from nonclinical depression. Physician and Patient 2:10-23, 1983. 3. Nelson JC, Price LH. Psychopharmacology. Chapter in: Psychiatry: Pretest Self-Assessment and Review, 3rd ed, Nelson JC, Greenfeld D. (eds), McGraw-Hill, Inc, New York, pp 158-183, 1984. 4. Price LH (Primary consultant). Beta-blockers for anxiety. Medical Letter 26:61-62, June 22, 1984. 5. Price LH, Charney DS. Receptor sensitivity in depression. Psychiatry Letter 4:71-76, 1986. 6. Charney DS, Heninger GR, Price LH, Breier A. Major depression and panic disorder: Diagnostic and neurobiological relationships. Psychopharm Bull 22:503-511, 1986.
15
Lawrence H. Price, MD
7. Atkinson JW, Bongort K, Price LH. Explorations using computer simulation to comprehend thematic apperceptive measurement of motivation. Chapter in: Motivation, Thought, and Action, Kuhl J, Atkinson JW. (eds), Praeger Publishers, New York, pp 97-124, 1986. 8. Goodman WK, Charney DS, Heninger GR, Price LH, Woods SW. Clinical spectrum of action of tricyclic antidepressants: Possible relationships to receptor actions. Chapter in: Biological Psychiatry 1985 (Proceedings of the IVth World Congress of Biological Psychiatry), Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM. (eds), Elsevier Science Publishing, New York, pp 906-908, 1986. 9. Price LH (Consultant). Psychiatric aspects of chronic pain. Chapter in: Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives, Committee on Pain, Disability, and Chronic Illness Behavior, Institute of Medicine, National Academy Press, Washington, DC, pp 165-185, 1987. 10. Price LH. Antidepressants. Chapter in: Depression & Mania: Modern Lithium Therapy, Johnson FN (ed), IRL Press, Oxford, UK, pp 161-166, 1987. 11. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR. Specificity of noradrenergic dysregulation in panic disorder. Chapter in: Progress in Catecholamine Research, Part C: Clinical Aspects, Belmaker RH, Sandler M, Dahlstrom A (eds), Alan R Liss, Inc, New York, pp 343-347, 1988. 12. Goodman WK, Charney DS, Rasmussen SA, Price LH, Woods SW, Heninger GR. Role of noradrenergic and serotonergic systems in obsessive compulsive disorder: Findings from pharmacological challenge studies. Chapter in: Progress in Catecholamine Research, Part C: Clinical Aspects, Belmaker RH, Sandler M, Dahlstrom A (eds), Alan R Liss, Inc, New York, pp 369-375, 1988. 13. Price LH (Primary consultant). Fluoxetine for depression. Medical Letter 30:45-47, April 22, 1988. 14. Heninger GR, Charney DS, Price LH. Noradrenergic and serotonergic receptor system function in panic disorder and depression. Acta Psychiatr Scand 77(Supp 341):138-150, 1988. 15. Price LH. Aggression and violence: A medical approach to pharmacological treatment. Yale Psychiatr Quart 10:5-8, 1988. 16. Goodman WK, Price LH. Antidepressants in obsessive compulsive disorder. Yale Psychiatr Quart 11:8-12, 1988. 17. Price LH. Lithium augmentation of tricyclic antidepressants. Chapter in: Treatment of Tricyclic Resistant Depression, Extein I (ed), American Psychiatric Press, Washington, DC, pp 49-79, 1989. 18. Goodman WK, Price LH, Charney DS. Fluvoxamine in obsessive compulsive disorder. Psychiatr Ann 19:92- 96,1989. 19. Heninger GR, Charney DS, Price LH, Delgado P, Woods S, Goodman W. Effects of serotonergic agonists on neuroendocrine responses in rhesus monkeys and patients with depression and anxiety disorders. Chapter in: Clinical Pharmacology in Psychiatry, Dahl SG, Gram LG (eds), Springer-Verlag, Berlin, pp 94-104, 1989. 20. Goodman WK, Price LH, Rasmussen SA, Heninger GR, Charney DS. Fluvoxamine as an antiobsessional agent. Psychopharmacol Bull 25:31-35, 1989. 21. Heninger GR, Charney D, Price L, Delgado P, Woods S, Goodman W. Neuroendocrine effects of serotonin agonists in rhesus monkeys, healthy humans, and patients with depression or anxiety disorders: Effects of antidepressant treatment. Chapter in: Serotonin: From Cell Biology to Pharmacology and Therapeutics, Paoletti R, et al (eds), Kluwer Academic Publishers, pp 559-563, 1990. 22. Price LH. Pharmacological strategies in refractory depression. Chapter in: American Psychiatric Press Annual Review of Psychiatry, Vol 9, Tasman A, Goldfinger S M, Kaufmann CA, (eds), American Psychiatric Press, Washington, DC, pp 116-131, 1990. 23. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry 51(4, suppl):44-50, 1990. 24. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR. Noradrenergic dysregulation in panic disorder. Chapter in: Neurobiology of Panic Disorder, Ballenger JC (ed), Alan R Liss, Inc, New York, NY, pp 91-105, 1990. 25. Goodman WK, Price LH. Rating scales for obsessive compulsive disorder. Chapter in: Obsessive Compulsive Disorders: Theory and Management, 2nd Ed, Jenike MJ, Baer L, Minichiello WE (eds), PSG Publishing Co, Littleton, MA, pp 154-166, 1990. 26. Malison RT, Price LH. Panic states. Curr Opin Psychiatry, 3:229-234, 1990. 27. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder?. J Clin Psychiatry 51(8, suppl):36-43, 1990. 28. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuro-Psychopharmacol & Biol Psychiatry 14:459-472, 1990. 29. Price LH. Serotonin reuptake inhibitors in depression and anxiety: An overview. Ann Clin Psychiatry 2:165-172, 1990.
16
Lawrence H. Price, MD
30. Charney DS, Delgado PL, Price LH, Heninger GR. The receptor sensitivity hypothesis of antidepressant action: A review of antidepressant effects on serotonin function. Chapter in: The Role of Serotonin in Psychiatric Disorders, Brown S-L, Van Praag HM (eds), Brunner/Mazel, New York, NY, pp 27-56, 1991. 31. Goodman WK, Price LH, Woods SW, Charney DS. Pharmacologic challenges in obsessive-compulsive disorder. Chapter in: The Psychobiology of Obsessive Compulsive Disorder, Zohar J, Insel T, Rasmussen S (eds), Springer Publishing, New York, pp 162-186, 1991. 32. Malison RT, Price LH. Panic disorder: Neurobiological advances. Curr Opin Psychiatry 4:255-261, 1991. 33. Charney DS, Delgado PL, Southwick SM, Krystal JH, Price LH, Heninger GR. Current hypotheses of the mechanism of antidepressant treatments: Implications for the treatment of refractory depression. Chapter in: Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, Amsterdam JD (ed), Raven Press, New York, pp 23-40, 1991. 34. Goodman WK, Price LH. Fluvoxamine in the treatment of obsessive-compulsive disorder. Chapter in: Current Treatments of Obsessive-Compulsive Disorder, Pato MT, Zohar J (eds), American Psychiatric Press, Washington, DC, pp 45-59, 1991. 35. Woods SW, O'Malley S, Martini BL, McDougle CJ, Price LH, Krystal JH, Hoffer PB, Kosten TR. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: Preliminary results. Prog Neuro-Psychopharmacol & Biol Psychiatry 15:649-662, 1991. 36. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS. Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharm Bull 27:321-330, 1991. 37. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies. J Clin Psychiatry 53(4, suppl):17-28, 1992. 38. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 53(4, suppl):29-37, 1992. 39. McDougle CJ, Goodman WK, Price LH. New research on the neurobiology of obsessive compulsive disorder. Curr. Opin. Psychiatry 5:249-254, 1992. 40. Delgado PL, Price LH, Heninger GR, Charney DS. Neurochemistry. Chapter in: Handbook of Affective Disorders, 2nd Ed, Paykel ES (ed), Churchill Livingstone, Edinburgh, UK, pp 219-253, 1992. 41. Black J, McDougle CJ, Price LH. Clinical neurobiology of cocaine administration and abstinence. Chapter in: Clinician's Guide to Cocaine Addiction: Theory, Research, and Treatment, Kosten TR, Kleber HD (eds), Guilford Publications, New York, pp 151-171, 1992. 42. Heninger GR, Delgado PL, Charney DS, Price LH, Aghajanian GK. Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. J Chem Neuroanat 5:347-348, 1992. 43. Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Internat Clin Psychopharmacology 7(suppl 1):35-38, 1992. 44. Goodman WK, Price LH. Assessment of severity and change in obsessive compulsive disorder. Chapter in: Obsessional Disorders. In the series: Psychiatric Clinics of North America, Vol 15(4), Jenike MA (ed), WB Saunders, Philadelphia, pp 861-869, 1992. 45. Redmond DE Jr, Robbins RJ, Naftolin F, Marek KL, Vollmer TL, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, Sass KJ, Elsworth JD, Kier EL, Makuch R, Hoffer PB, Gulanski BI, Serrano C, Spencer DD. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: Preliminary results in four patients. Chapter in: Molecular and Cellular Approaches to the Treatment of Neurological Disease. In the series: Research Publications: Assoc for Research in Nerv and Mental Dis, Vol 1, Waxman SG (ed), Raven Press, New York, pp 325-359, 1993. 46. McDougle CJ, Goodman WK, Price LH. The pharmacotherapy of obsessive compulsive disorder. Pharmacopsychiatry 26(suppl):24-29, 1993. 47. Goodman WK, McDougle CJ, Barr LC, Aronson S, Price LH. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54(6, suppl):16-26, 1993. 48. Sherman TS, McDougle CJ, Price LH. Paroxetine: A new serotonin reuptake inhibitor for the treatment of depression. Conn Med 57:587-592, 1993. 49. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive compulsive disorder: Implications for treatment and pathogenesis. Chapter in: Psychopharmacology II. In the series: Psychiatric Clinics of North America, Vol 16(4), Dunner DL (ed), WB Saunders, Philadelphia, pp 749-766, 1993. 50. Barr LC, Goodman WK, Price LH. The serotonin hypothesis of obsessive compulsive disorder. Internat Clin Psychopharmacology 8(suppl 2):79-82,1993.
17
Lawrence H. Price, MD
51. McDougle CJ, Price LH, Volkmar FR. Recent advances in the pharmacotherapy of autism and related conditions. Chapter in: Psychoses and Pervasive Developmental Disorders. In the series: Child and Adolescent Psychiatric Clinics of North America, Vol 3(1), Volkmar FR (ed), WB Saunders, Philadelphia, pp 71-89, 1994. 52. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum OCD. J Clin Psychiatry 55(3, suppl):24-31, 1994. 53. Goodman WK, Rasmussen SA, Foa E, Price LH. Obsessive compulsive disorder. Chapter in: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS (eds), Raven Press, New York, pp 431-466, 1994. 54. Price LH, Goddard AW, Barr LC, Goodman WK. Pharmacological challenges in anxiety disorders. Chapter in: Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds), Raven Press, New York, pp 1311-1323, 1995. 55. Price LH, Malison RT, McDougle CJ, Pelton GH. Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. CNS Drugs 5:311-320, 1996. 56. Cappiello A, Price LH. Lithium in the treatment of refractory depression. J Irish Coll Phys Surg 25:194-197, 1996. 57. Carpenter L, McDougle CJ, Epperson NE, Price LH. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Safety 15(2):116-134. 1996. 58. Price LH, Rasmussen SA. Stress and depression: Is neuroimmunology the missing link? Harvard Rev Psychiatry 5:108-112, 1997. 59. Price LH, Carpenter LL. The use of antiglucocorticoids for treating depression. Medscape Ment Health 2(8),
18
Lawrence H. Price, MD
Estresse Pós-Traumático – TEPT [Posttraumatic Stress Disorder – PTSD], Mari JJ, Mello MF, Bressan RA, Andreoli SB (eds), Editora Manole, Sao Paulo, Brazil, 2005. 73. Carpenter LL, Friehs GM, Tyrka AR, Rasmussen S, Price LH, Greenberg BD. Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. Medicine & Health/Rhode Island 89(4):137-141, 2006. 74. Tyrka AR, Carpenter LL, Carvalho JP, Price LH. Biomarkers in the human stress system: Do they signal risk for depression? Medicine & Health/Rhode Island 89(5):180-182, 2006. 75. Tyrka AR, Price LH, Mello MF, Mello AF, Carpenter LL. Psychotic major depression: A benefit-risk assessment of treatment options. Drug Safety 29(6):491-508. 2006. 76. Mello AF, Juruena MF, Pariante CM, Tyrka AR, Price LH, Carpenter LL, Del Porto JA. Depression and stress: Is there an endophenotype? Rev Bras Psiquiatr 29(Suppl I):S13-18, 2007. 77. Park MC, Goldman MA, Carpenter LL, Price LH, Friehs GM. Vagus nerve stimulation for depression: rationale, anatomical and physiological basis of efficacy and future prospects. Acta Neurochir Suppl 97(Pt 2):407-416, 2007. 78. Philip N, Carpenter LL, Tyrka AR, Price LH. Using atypical antipsychotics to augment treatment of nonpsychotic unipolar depression. Directions in Psychiatry 29(1):51-59, 2009. 79. Mello MF, Faria AA, Mello AAF, Carpenter LL, Tyrka AR, Price LH. Childhood maltreatment and adult psychopathology: Pathways to hypothalamic-pituitary-adrenal axis dysfunction. Rev Bras Psiquiatr 31(Suppl 2):S41- 48, 2009. 80. Price LH (field editor for clinical psychopharmacology). In: Encyclopedia of Psychopharmacology, Stolerman I (ed), Springer, Berlin/Heidelberg, Germany, 2010. 81. Price LH. Major and minor and mixed anxiety-depressive disorders. Essay in: Encyclopedia of Psychopharmacology, Stolerman I (ed), Springer, Berlin/Heidelberg, Germany, pp 745-749, 2010. 82. Khoury LM, Carpenter LL, Price LH, Tyrka AR. Early-life stress and altered neuroendocrine function: Risk for mood and anxiety disorders. Directions in Psychiatry 30(2):63-75, 2010. 83. Price LH, Whiteley L. Effective pharmacotherapy for obsessive-compulsive disorder in adults. European Psychiatr Rev 3(2):58-62, 2010.
Miscellaneous:
1. Price LH. Diagnosing depression with DST. Consultant 23(2):25-26, 1983. 2. Price LH. Tricyclic maintenance for depression. Consultant 23(3):27, 1983. 3. Price LH. Tricyclics--single v multiple dosing. Consultant 23(7):29-31, 1983. 4. Price LH. Therapy for stress reaction. Consultant 23(10):27-28, 1983. 5. Price LH, Charney DS, Heninger GR. Manic symptoms following addition of lithium to antidepressant treatment [Lttr to the Ed]. J Clin Psychopharmacol 4:361-362, 1984. 6. Price LH. Another use for clonidine. Consultant 24(2):268, 1984. 7. Price LH. Megavitaminosis can be depressing. Consultant 24(3):300, 1984. 8. Price LH. Unexplained burning sensation. Consultant 26(3):14-15, 1986. 9. Price LH. Anxiety vs. depression--how to tell them apart. Consultant 26(6):15-16, 1986. 10. Price LH, Nelson JC. Alcoholism and affective disorder [Lttr to the Ed]. Am J Psychiatry 143:1067-1068, 1986. 11. Price LH. Mania induced by lithium augmentation [Lttr to the Ed]. Am J Psychiatry 144:389, 1987. 12. Palumbo JM, Price LH. Opening the mouth to abolish auditory hallucinations [Lttr to the Ed]. Am J Psychiatry 145:767, 1988. 13. Charney DS, Price LH, Brier, A. In reply to "The course of panic attacks and agoraphobia" [Lttr to the Ed]. Arch. Gen. Psychiatry 45:502, 1988. 14. Price LH, Heninger GR. Question the Experts: Can yohimbine be used to treat the orthostatic hypotension associated with the use of desipramine and other antidepressants? J Clin Psychopharmacol 8:384, 1988. 15. Goodman WK, Price LH. Guidelines to the diagnosis of obsessive compulsive disorder. Anafranil Treatment Program Ciba-Geigy, 1988. 16. Price LH. Book review of The Measurement of Depression by Marsella AJ, et al (eds). J Nerv Ment Dis 176:701, 1988. 17. Seibyl JP, Krystal JH, Price LH, Charney DS. Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension [Lttr to the Ed]. J Clin Psychopharmacol 9:67-68, 1989. 18. Price LH. Question the Experts: What is the duration for augmentation with T3 or lithium in resistant depression? J Clin Psychopharmacol 9:73,1989.
19
Lawrence H. Price, MD
19. Price LH, Goodman, WK. Obsessive-compulsive disorder: A treatment review [Lttr to the Ed]. J Clin Psychiatry 50:231-232,1989. 20. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence [Lttr to the Ed]. Am J Psychiatry 146:1349, 1989. 21. McDougle CJ, Goodman WK, Delgado PL, Price LH. Pathophysiology of obsessive-compulsive disorder [Lttr to the Ed]. Am J Psychiatry 146:1350-1351, 1989. 22. Price LH, Krystal JH, Heninger GR, Ricaurte GA. In reply to "Second thoughts on 3,4- methylenedioxymethamphetamine (MDMA) neurotoxicity" [Lttr to the Ed]. Arch Gen Psychiatry 47:289, 1990. 23. Price LH, Charney DS, Delgado PL, Heninger GR. In reply to "Lithium treatment effect on serotonin function" [Lttr to the Ed]. Arch Gen Psychiatry 47:290, 1990. 24. Price LH. When physical complaint persists despite negative workup. Consultant 31(2):13, 1991. 25. Goodman WK, Price LH. In reply to "Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers" [Lttr to the Ed]. Arch Gen Psychiatry 48:484, 1991. 26. Price LH. Chronic headache of unknown origin. Consultant 31(7):14-15, 1991. 27. McCance-Katz EF, Price LH. Depression associated with vitamin A intoxication [Lttr to the Ed]. Psychosomatics 33:117-118, 1992. 28. Kosten TR, Price LH. Commentary: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180:353-354, 1992. 29. Price LH, Charney DS, Heninger GR. Serotonin syndrome [Lttr to the Ed]. Am J Psychiatry 149:1116-1117, 1992. 30. Price LH, Delgado PL, Charney DS, Heninger GR. In reply to "Serotonin function in depression: Effects of seasonality?" [Lttr to the Ed]. Am J Psychiatry 149:1277, 1992. 31. Barr LC, Goodman WK, Price LH. Acute exacerbation of body dysmorphic disorder during tryptophan depletion [Lttr to the Ed]. Am J Psychiatry 149:1406-1407, 1992. 32. Price LH. The treatment of refractory depression: Role of the serotonin reuptake inhibitors. Can Rev Affect Disord 2(4):1-3, 1992. 33. Price LH. Concern for self-injury in bipolar disorder. Consultant 33(6):28, 1993. 34. Delgado P, Charney DS, Price LH. In reply to "Risk of tryptophan depletion following amino acid supplementation" [Lttr to the Ed]. Arch Gen Psychiatry 50:1000-1001, 1993. 35. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [Lttr to the Ed]. Am J Psychiatry 151:289, 1994. 36. Price LH, Heninger GR. In reply to “Lithium in the treatment of mood disorders” [Lttr to the Ed]. N Engl J Med 332:128, 1995. 37. Price LH. Coactive pharmacologic strategies for the management of refractory depression. Can Rev Affect Disord, 5(3):1-8, 1995. 38. Nelson JC, Price LH. Lithium or desipramine augmentation of fluoxetine treatment [Lttr to the Ed]. Am J Psychiatry 152:1538-1539, 1995. 39. Price LH. Mood disorders: Approaching the millenium. Yale Psychiatry 5(1):3-4, 1995. 40. Price LH, Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR. In reply to “Responses to mCPP stimulation in depressed patients” [Lttr to the Ed]. Am J Psychiatry 152:1834-1835, 1995. 41. Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling [Lttr to the Ed]. Am J Psychiatry 153:445, 1996. 42. McDougle CJ, Epperson CN, Price LH. Obsessive-compulsive symptoms with neuroleptics [Lttr to the Ed]. J Am Acad Child Adolesc Psychiatry 35(7):837-838, 1996. 43. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in trichotillomania [Lttr to the Ed]. Biol Psychiatry 40:559-560, 1996. 44. Price LH. Review of "The growth hormone response to apomorphine at 4 days postpartum in women with a history of major depression. McIvor RJ, et al. J Affect Disord 1996;40:131-136." J Dep Disord: Index Rev 2(1):5, 1997. 45. Price LH. Review of "Increased prolactin response to buspirone in chronic fatigue syndrome. Sharpe M, et al. J Affect Disord 1996;41:71-76." J Dep Disord: Index Rev 2(1):5, 1997. 46. Price LH. Review of "Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid-receptor gene. Matthes HWD, et al. Nature 1996;383:819-823." J Dep Disord: Index Rev 2(1):7, 1997. 47. Price LH. Review of "Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Spina M, et al. Science 1996;273:1561-1564." J Dep Disord: Index Rev 2(1):11, 1997. 48. Price LH. Review of "Epidemiological data suggest antidepressants reduce suicide risk among depressives. Isacsson G, et al. J Affect Disord 1996;41:1-18." J Dep Disord: Index Rev 2(1):12, 1997.
20
Lawrence H. Price, MD
49. Price LH. Review of "Evidence-based health policy--Lessons from the global burden of disease study. Murray CJL, Lopez AD. Science 1996;274:740-744." J Dep Disord: Index Rev 2(1):15, 1997. 50. Malison RT, Price LH, Nestler E J, Heninger GR, Duman RS. Efficacy of papaverine addition for treatment- refractory major depression [Lttr to the Ed]. Am J Psychiatry 154:579-580, 1997. 51. Price LH. Tele-Lecture Clinics: Augmentation strategies in refractory depression: An update. J Dep Disord: Index Rev 2(3):8-9, 1997. 52. Price LH. Review of "Association between the tryptophan hydroxylase gene and manic-depressive illness. Bellivier F, et al. Arch Gen Psychiatry 1998;55:33-37." J Dep Disord: Index Rev 3(2):13, 1998. 53. Price LH. Review of "Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. Neumeister A, et al. Arch Gen Psychiatry 1998;55:167-172." J Dep Disord: Index Rev 3(2):13, 1998. 54. Price LH. Review of "Electroencephalographic sleep profiles before and after cognitive behavior therapy of depression. Thase ME, et al. Arch Gen Psychiatry 1998;55:138-144." J Dep Disord: Index Rev 3(2):14, 1998. 55. Price LH. Review of "Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Blazer DG, et al. Br J Psychiatry 1998;172:164-167." J Dep Disord: Index Rev 3(2):14, 1998. 56. Price LH. Review of "A factor analysis of the signs and symptoms of mania. Cassidy YF, et al. Arch Gen Psychiatry 1998;55:27-32." J Dep Disord: Index Rev 3(2):15, 1998. 57. Price LH. Review of "Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. Levitan RD, et al. Arch Gen Psychiatry 1998;55:244-249." J Dep Disord: Index Rev 3(2):15, 1998. 58. Price LH, Rasmussen SA, Eisen JL. The natural history of obsessive-compulsive disorder [Commentary]. Arch Gen Psychiatry 56:131-132, 1999. 59. Gordon A, Price LH. Mood stabilization and weight loss with topiramate [Lttr to the Ed]. Am J Psychiatry 156:968- 969, 1999. 60. Price LH. Commentary on "Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Kulin NA, et al. JAMA 1998:279;609-610." Evid-based Healthcare 3:43, 1999. 61. Phillips KA, Rasmussen SA, Price LH. Treating imagined ugliness [Commentary]. Arch Gen Psychiatry 56:1041- 1042, 1999. 62. Price LH, Lebel J. Dextromethorphan-induced psychosis [Lttr to the Ed]. Am J Psychiatry 157:304, 2000. 63. Nelson JC, Nierenberg A, Price LH. Augmentation strategies in treatment-resistant depression. Psychiatric Update 20(2):1-9, 2000. 64. Price LH, Flach F. Interview: Treatment of refractory depression. Essent Psychopharmacology 3(4):71-82, 2000. 65. Price LH, Gagne GG Jr, Carpenter LL, Furman MJ. In reply to "Continuation ECT for chronic depression" [Lttr to the Ed]. Am J Psychiatry 158:1933-1934, 2001. 66. Blier P, Price LH, Delgado PL. SSRIs vs. SNRIs: Mechanisms of action. CNS Spectrums 6(monogr 12):1-8, 2001 [also in: Primary Psychiatry 8(monogr 12):1-8, 2001]. 67. Price LH. Book review of Treatment of Recurrent Depression by Greden JF (ed). J Nerv Ment Dis 190(3):204-205, 2002. 68. Price LH. Letter from the editor. Brown Univ Psychopharm Update 13(4):4, 2002. 69. Price LH. Letter from the editor. Brown Univ Psychopharm Update 13(5):4, 2002. 70. McDougle CJ, Price LH. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor- refractory obsessive-compulsive disorder may be dose-dependent [Lttr to the Ed]. Arch Gen Psychiatry 59(5):472- 473, 2002. 71. Price LH. Letter from the editor. Brown Univ Psychopharm Update 13(7):3, 2002. 72. Price LH. Letter from the editor. Brown Univ Psychopharm Update 13(9):5, 2002. [Reprinted in: Calif Soc Addict Med. CSAM News 28(3):7, 2003] 73. Price LH. Letter from the editor. Brown Univ Psychopharm Update 13(12):4, 2002. 74. Price LH. "…why are you going into psychiatry? "[Lttr to the Ed]. Medicine at Michigan 4(3):4, 2002. 75. Price LH. Letter from the editor. Brown Univ Psychopharm Update 14(2):1, 2003. 76. Price LH. Letter from the editor. Brown Univ Psychopharm Update 14(4):5, 2003. 77. Price LH. Letter from the editor. Brown Univ Psychopharm Update 14(10):3, 2003. 78. Price LH. Letter from the editor. Brown Univ Psychopharm Update 15(1):5, 2004. 79. Najjar F, Price LH. Citalopram and dystonia [Lttr to the Ed]. J Am Acad Child Adolesc Psychiatry 43(1):8-9, 2004. 80. Price LH. Book review of Handbook of Medical Psychiatry by Soares JC and Gershon S (eds). N Engl J Med 350(8):845, 2004. 81. Price LH. Letter from the editor. Brown Univ Psychopharm Update 15(4):1, 2004.
21
Lawrence H. Price, MD
82. Nelson JC, Mazure CM, Bowers MB, Jr, Jatlow PI, Price LH. In reply to "Regarding ‘Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind randomized study’: Optimizing initial interventions." [Lttr to the Ed]. Biol Psychiatry 56(7):535-536, 2004. 83. Price LH. Letter from the editor. Brown Univ Psychopharm Update 15(10):5, 2004. 84. Price LH. Letter from the editor. Brown Univ Psychopharm Update 15(12):7, 2004. 85. Carpenter LL, Schecter JM, Siniscalchi J, Leon Z, Price LH. A case series describing orlistat use in patients on psychotropic medications. Medicine & Health/Rhode Island 87(12):375-377, 2004. 86. Price LH. Letter from the editor: Glucose metabolism. Brown Univ Psychopharm Update 16(4):4, 2005. 87. Price LH. Book review of Anxiety Disorders in Adults: A Clinical Guide by Starcevic V. N Engl J Med 352(16):1727, 2005. 88. Price LH. Letter from the editor: Quetiapine for bipolar disorder. Brown Univ Psychopharm Update 16(9):7, 2005. 89. Price LH. Letter from the editor: Comment on the Calabrese et al study. Brown Univ Psychopharm Update 17(2):4, 2006. 90. Wier LM, Tavares SB, Tyrka AR, Price LH, Carpenter LL. Levetiracetam-induced depression in a healthy adult [Lttr to the Ed]. J Clin Psychiatry 67(7):1159-1160, 2006. 91. Price LH. Letter from the editor: A roadmap for the STAR*D studies. Brown Univ Psychopharm Update 17(12):5, 2006. 92. Price LH. Editor’s commentary: Dopamine agonists and valvular heart disease: The unknown unknowns. Brown Univ Psychopharm Update 18(4):5-6, 2007. 93. Price LH. Editor’s commentary: Atomoxetine augmentation for depression: Accentuate the negative. Brown Univ Psychopharm Update 18(6):7, 2007. 94. Price LH, Tyrka AR. Adjunctive antidepressant treatment for bipolar depression [Lttr to the Ed]. N Engl J Med 357(6):614, 2007. 95. Price LH. Editor’s commentary: SSRIs: A risk factor for bone loss? Brown Univ Psychopharm Update 18(10):5, 2007. 96. Spring B, Hitsman B, Baruah S, Price LH. In reply to "Interpreting tryptophan depletion in tobacco smokers" [Lttr to the Ed]. Biol Psychiatry 63(4):e31-e32, 2008. 97. Price LH. Editor’s commentary: Psychiatric gene testing: Are we ready? Brown Univ Psychopharm Update 19(4):5, 2008. 98. Price LH. Editor’s commentary: What does a woman want? Brown Univ Psychopharm Update 19(10):6, 2008. 99. Price LH. Editor’s commentary: Of silk purses and sows ears. Brown Univ Psychopharm Update 19(12):4, 2008. 100. Price LH. Editor’s commentary: Bad to the bone. Brown Univ Psychopharm Update 20(3):4, 2009. 101. Price LH. Editor’s commentary: Tough choices on atypicals. Brown Univ Psychopharm Update 20(5):4, 2009. 102. Price LH. Atypical antipsychotic drugs and the risk of sudden cardiac death [Lttr to the Ed]. N Engl J Med 360(20):2137, 2009. 103. Price LH. Editor’s commentary: A different kind of stimulus package. Brown Univ Psychopharm Update 20(9):3, 2009. 104. Price LH. Editor’s commentary: When received wisdom fails: Psychotherapy for treatment-resistant depression. Brown Univ Psychopharm Update 21(2):4-5, 2010. 105. Price LH. Looking at ways to treat depression [Lttr to the Ed]. New York Times, January 12, 2010. 106. Price LH. Editor’s commentary: Preventing PTSD. Brown Univ Psychopharm Update 21(4):5, 2010. 107. Tyrka AR, Price LH, Carpenter LL, Anderson GM. In reply to: "Childhood maltreatment and hypothalamic-pituitary- adrenal axis reactivity" [Lttr to the Ed]. Biol Psychiatry 67(11):e61-e62, 2010. 108. Price LH. Editor’s commentary: How many antidepressants does it take to treat depression? Brown Univ Psychopharm Update 21(6):5, 2010. 109. Tyrka AR, Price LH, Kao H-T, Porton B, Carpenter LL. In reply to: "No correlation between childhood maltreatment and telomere length" [Lttr to the Ed]. Biol Psychiatry 68(6):e23-24, 2010. 110. Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. Commentary: The current crisis of confidence in antidepressants. J Clin Psychiatry 72(1):27-33, 2011. PMID: 21272514 [Also published online as: Crisis of confidence: Antidepressant risk versus benefit. J Clin Psychiatry 72(3):e11, 2011. PMID: 21272514 http://www.cmeinstitute.com/psychlopedia/depression/13coc/sec1/section.asp] 111. Price LH, Steckler T. Early life stress and psychopharmacology [Editorial]. Psychopharmacology 214(1):1-3, 2011. PMID: 21327757 112. Price LH. Editor’s response: Comment on the February (2011) Nuedexta handout. Brown Univ Psychopharm Update 22(4):4, 2011.
22
Lawrence H. Price, MD
113. Price LH. Editor’s commentary: Pharmacogenetics and the treatment of alcoholism. Brown Univ Psychopharm Update 22(6):4, 2011. 114. Price LH. Editor’s commentary: The myth of medical marijuana. Brown Univ Psychopharm Update 22(9):4, 2011. 115. Price LH. Editor’s commentary: Cardiac risks with citalopram: Now what do we do? Brown Univ Psychopharm Update 22(11):4, 2011. 116. Minhas HM, Elliot MB, Price LH. Altered mental status due to hand sanitizer ingestion [Lttr to the Ed]. Br J Psychiatry December 5, 2011. http://bjp.rcpsych.org/letters/ 117. Price LH. Editor’s commentary: Why psychiatrists should treat smoking. Brown Univ Psychopharm Update 23(2):4- 5, 2012. 118. Price LH. Editor’s commentary: Adverse effects of psychotropic drugs: Where we are now. Brown Univ Psychopharm Update 23(6):4, 2012. 119. Fulton AT, Sullivan JK, Price LH. Concurrent medical and psychiatric care at a freestanding academic psychiatric hospital. Psychiatr Serv. In review.
ABSTRACTS
1. Price LH, Heninger GR, Charney DS. Effects of alpha 2-adrenoceptor blockade in depression. Amer Psychiatr Assoc New Research Abstr #NR56, May, 1984. 2. Charney DS, Heninger GR, Price LH. Response to yohimbine, an alpha-2 adrenoceptor blocker, in panic disorder and depression. Abstr Amer Coll Neuropsychopharm p 46, December, 1984. 3. Heninger GR, Charney DS, Price LH. Plasma MHPG and depressive symptoms during antidepressant treatment: Evaluation of drug combination to produce a more rapid antidepressant effect. Abstr Amer Coll Neuropsychopharm p 73, December, 1984. 4. Price LH, Charney DS, Heninger GR. Effects of I.V. L-tryptophan during tranylcypromine treatment of depression. Abstr Amer Coll Neuropsychopharm p 122, December, 1984. 5. Price LH, Heninger GR. Cortisol response to yohimbine in depression. Amer Psychiatr Assoc New Research Abstr p 56 (#NR85), May, 1985. 6. Charney DS, Heninger GR, Price LH. Noradrenergic function in anxiety and depression. Proc Amer Psychiatr Assoc p 69, May, 1985. 7. Charney DS, Price LH, Heninger GR, Rubin AL. Noradrenergic activity and HPA dysfunction. Proc Amer Psychiatr Assoc p 137, May, 1985. 8. Charney DS, Heninger GR, Price LH. Noradrenergic and serotonergic receptor function: Relationship to the pathogenesis and treatment of affective disorders. Abstr IVth World Cong Biol Psychiatry p 40 (#123.6), September, 1985. 9. Price LH, Charney DS, Heninger GR. Effects of yohimbine on cortisol in depression. Abstr IVth World Cong Biol Psychiatry p 97 (#149.4), September, 1985. 10. Heninger GR, Charney DS, Price LH. Clinical neurobiologic assessment of "presynaptic" and "postsynaptic" serotonergic function in major depression: Effects of antidepressant treatment. Abstr IVth World Cong Biol Psychiatry p 131 (#209.2), September, 1985. 11. Charney DS, Heninger GR, Price LH, Goodman WK, Woods SW. Clinical spectrum of action of tricyclic antidepressants: Possible relationships to receptor actions. Abstr IVth World Cong Biol Psychiatry p 449 (#616.2), September, 1985. 12. Price LH, Charney DS, Heninger GR. Effects of trazodone on alpha-2 adrenoceptor functions in depression. Soc Neurosci Abstr 11(1):184 (60.2), November, 1985. 13. Heninger GR, Charney DS, Price LH. Neuroendocrine and behavioral effects of an I.V. infusion of a 5-HT1B agonist (MCPP) and L-tryptophan in rhesus monkeys, healthy humans, and depressed patients. Abstr Amer Coll Neuropsychopharm p 65, December, 1985. 14. Heninger GR, Charney DS, Price LH. Effects of withdrawal of long-term antidepressant treatment on monoamine metabolism and receptor sensitivity. Abstr Amer Coll Neuropsychopharm p 96, December, 1985. 15. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory melancholia. Abstr Amer Coll Neuropsychopharm p 113, December, 1985. 16. Price LH, Heninger GR, Charney DS. Reserpine augmentation in refractory melancholia. Amer Psychiatr Assoc New Research Abstr p 83 (#NR133), May, 1986. 17. Price LH, Heninger GR, Charney DS. Lithium augmentation of tricyclic antidepressants. Proc Amer Psychiatr Assoc p 65, May, 1986.
23
Lawrence H. Price, MD
18. Goodman WK, Price LH, Rasmussen SA, Charney DS, Woods SW, Heninger GR. Evidence for abnormal serotonergic function in obsessive compulsive disorder. Soc Neurosci Abstr 12(2): 1161 (317.6), November, 1986. 19. Price LH, Charney DS, Heninger GR. Effects of trazodone on serotonergic function in depression. Soc Neurosci Abstr 12(1):473 (30.3), November, 1986. 20. Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on neuroendocrine, mood, and cardiovascular responses to intravenous L-tryptophan in depressed patients. Abstr Amer Coll Neuropsychopharm p 179, December, 1986. 21. Goodman WK, Charney DS, Rasmussen SA, Price LH, Woods SW, Heninger GR. Serotonin and obsessive compulsive disorder. Proc Amer Psychiatr Assoc p 47, May, 1987. 22. Heninger GR, Charney DS, Woods SW, Price LH, Goodman WK. Serotonergic agonists in anxiety and depression. Proc Amer Psychiatr Assoc p 175, May, 1987. 23. Delgado PL, Price LH, Charney DS, Heninger GR. Fluvoxamine in refractory depression. Amer Psychiatr Assoc New Research Abstr p 43 (#NR43), May, 1987. 24. Nierenberg AA, Price LH, Charney DS, Heninger GR. After lithium augmentation: A retrospective study. Amer Psychiatr Assoc New Research Abstr p 44 (#NR44), May, 1987. 25. Goodman WK, Charney DS, Price LH, Rasmussen SA, Heninger GR, Delgado PL, Krystal JH. Fluvoxamine in obsessive compulsive disorders. Amer Psychiatr Assoc New Research Abstr p 118 (#NR183), May, 1987. 26. Goodman WK, Charney DS, Price LH, Delgado PL, Rasmussen SA, Heninger GR. Fluvoxamine in OCD: Antiobsessional or antidepressant? Soc Neurosci Abstr 13(1):215 (66.8), November, 1987. 27. Delgado PL, Charney DS, Price LH, Anderson G, Landis H, Heninger GR. Dietary tryptophan restriction produces an upregulation of the neuroendocrine response to infused tryptophan in healthy human subjects. Soc Neurosci Abstr 13(1):227 (68.21), November, 1987. 28. Price LH, Charney DS, Delgado PL, Heninger GR. Enhancement of serotonergic function by lithium in affective disorder patients. Soc Neurosci Abstr 13(2):883 (246.5), November, 1987. 29. Delgado PL, Price LH, Heninger GR. Upregulation of the prolactin response to infused tryptophan by dietary tryptophan restriction in healthy human subjects. Abstr Amer Coll Neuropsychopharm p 170, December, 1987. 30. Price LH, Delgado PL, Heninger GR. Serotonergic function in affective disorder patients: Effects of desipramine, fluvoxamine, and lithium treatment. Abstr Amer Coll Neuropsychopharm p 193, December, 1987. 31. Heninger GR, Charney DS, Price LH. Effects of serotonin receptor agonists and antagonists on behavior and neuroendocrine function in rhesus monkeys, healthy humans, and depressed patients. Abstr Amer Coll Neuropsychopharm p 54, December, 1987. 32. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CI, Kleber HD. Opioid detoxification using buprenorphine. Amer Psychiatr Assoc New Research Abstr p 71 (#NR119), May, 1988. 33. Delgado PL, Price L, Charney DS, Aghajanian GK, Landis H, Heninger GR. Tryptophan depletion alters mood in depression. Amer Psychiatr Assoc New Research Abstr p 89 (#NR164), May, 1988. 34. Price LH, Charney DS, Delgado PL, Heninger GR. Effects of thymoleptic drugs on serotonin function. Amer Psychiatr Assoc New Research Abstr p 89 (#NR165), May, 1988. 35. Goodman WK, Price LH, Rasmussen SA, Mazure C, Heninger GR, Charney DS: Yale-Brown Obsessive Compulsive Scale: Validity. Amer Psychiatr Assoc New Research Abstr p 128 (#NR261), May, 1988. 36. Price LH, Charney DS, Delgado PL, Heninger GR. Neuroendocrine effects of intravenous L-tryptophan. Soc Biol Psychiatry p 328, May, 1988. 37. Charney DS, Price LH, Delgado PL,Woods SW, Goodman WK, Heninger GR. Monoamine receptor function in affective disorders. Proc Amer Psychiatr Assoc p 145, May, 1988. 38. Goodman WK, Price LH, Heninger GR, Charney DS. Pharmacological treatment of obsessive compulsive disorder. Proc Amer Psychiatr Assoc p 190, May, 1988. 39. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney, D.S. Fluvoxamine treatment of obsessive compulsive disorder. Proc Amer Psychiatr Assoc p 260, May, 1988. 40. Goodman WK, Price LH, Delgado PL, Rasmussen SA, Palumbo J, Charney DS, Heninger GR. Fluvoxamine in the treatment of OCD. NCDEU Ann Mtg June, 1988. 41. Goodman WK, Price LH, Charney DS, Heninger GR. Fluvoxamine in OCD. Coll Internat Neuro-Psychopharm (in press). 42. Goodman WK, Price LH, Anderson GM, Delgado PL, Palumbo JM, Heninger GR, Charney DS. Serotonergic drug action and the treatment of OCD. Soc Neurosci Abstr 14(1):372( 152.1), November, 1988. 43. Price LH, Charney DS, Delgado PL, Heninger GR. Effects of thymoleptic drugs on serotonergic function in affective disorder patients. Soc Neurosci Abstr 14(1):46 (22.14), November, 1988.
24
Lawrence H. Price, MD
44. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Landis H, Heninger GR. Behavioral effects of acute tryptophan depletion in depressed and obsessive compulsive disorder (OCD) patients. Soc Neurosci Abstr 14(2):970 (390.20), November, 1988. 45. Heninger GR, Charney DS, Price LH, Woods SW, Goodman WK. Neuroendocrine and behavioral effects of 5-HT agonists in rhesus monkeys and patients: The effects of lithium. Abstr Amer Coll Neuropsychopharm p 76, December,1988. 46. Price LH, Charney DS, Delgado PL, Goodman W, Krystal JH, Woods SW, Heninger GR. Clinical studies of serotonin function using I.V. L-tryptophan. Abstr Amer Coll Neuropsychopharm p 77, December, 1988. 47. Charney DS, Price LH, Heninger GR. The receptor sensitivity hypothesis of antidepressant action: An evaluation and recommendation for future investigations. Abstr Amer Coll Neuropsychopharm p 114, December, 1988. 48. Goodman WK, Delgado PL, Price LH, Palumbo J, Rasmussen SA, Charney DS. Comparison of fluvoxamine and desipramine in OCD. Abstr Amer Coll Neuropsychopharm p 144, December, 1988. 49. Price LH, Ricuarte GA, Krystal JH, Heninger GH. Neuroendocrine and mood responses to I.V. L-Tryptophan in 3,4- methylenedioxymethamphetamine (MDMA) users: preliminary findings. Abstr Amer Coll Neuropsychopharm p 174, December, 1988. 50. Krystal JH, Kosten TR, Woods SW, Price, L., Smith EO, Zubal G, Hoffer P, Kleber H, Charney DS. Alterations in cerebral blood flow during naloxone-precipitated opiate withdrawal in humans. Abstr Amer Coll Neuropsychopharm p 175, December, 1988. 51. Delgado PL, Goodman WK, Price LH, Landis H, Aghajanian GK. Behavioral effects of acute tryptophan-depletion in depressed and obsessive compulsive disorder (OCD) patients. Abstr Amer Coll Neuropsychopharm p 184, December, 1988. 52. Delgado PL, Goodman WK, Price LH, Charney DS, Aghajanian GK, Heninger GR. Tryptophan depletion alters mood in OCD patients. Amer Psychiatr Assoc New Research Abstr p 190 (#NR351), May, 1989. 53. Krystal JH, Kosten TR, Woods SW, Seibyl J, Price LH, Zubal G, Hoffer P, Kleber HD, Charney DS. Opiate withdrawal effects on regional cerebral blood flow. Amer Psychiatr Assoc New Research Abstr p 198 (#NR372), May, 1989. 54. Seibyl JP, Charney DS, Krystal JH, Price LH, Heninger GR. 5-HT function in the biochemical response to MCPP. Amer Psychiatr Assoc New Research Abstr p 36(#NR20), May, 1989. 55. Palumbo JM, Price LH, Krystal JH, Woods SW, Charney DS, Kosten T, Kleber H. Dopamine function in cocaine withdrawal. Amer Psychiatr Assoc New Research Abstr p 105 (#NR167), May, 1989. 56. Goodman WK, Delgado PL, Price LH, Palumbo J, Rasmussen SA, Charney DS. Fluvoxamine versus desipramine in OCD. Amer Psychiatr Assoc New Research Abstr p 186 (#NR343), May, 1989. 57. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory OCD. Amer Psychiatr Assoc New Research Abstr p 189 (#NR350), May, 1989. 58. Goodman WK, Price LH, Anderson GM, Palumbo JH, Charney DS, Heninger GR. Drug response and obsessive compulsive disorder subtypes. Proc Amer Psychiatr Assoc pp 134-135, May, 1989 59. Krystal J, Kosten T, Woods, S, Seibyl J, Price L, Zubal G, Hoffer P, Kleber H, Charney D. Human regional cerebral blood flow alterations during naloxone-precipitated opiate withdrawal. Comm on Probs of Drug Dep, Inc Abstr 1989. 60. Price LH, Ricaurte GA, Krystal JH, Heninger GR. Responses to I.V. L-tryptophan in MDMA users. Comm on Probs of Drug Dep, Inc Abstr 1989. 61. Palumbo JM, Price LH, Woods SW, Kosten T, Krystal JH, Charney DS, Kleber H. Characterization of cocaine withdrawal: Dopamine function. Soc Neurosci Abstr 15(1): 251(#103.11), November,1989. 62. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Addition of dopamine antagonists in fluvoxamine-refractory obsessive compulsive disorder. Soc Neurosci Abstr 15(1):271(#109.20), November,1989. 63. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Heninger GR. Behavioral effects of acute tryptophan depletion in psychiatric patients and healthy subjects. Soc Neurosci Abstr 15(1):412(#166.13), November,1989. 64. Woods SW, O'Malley SS, Price LH, Krystal JH, Hoffer PB, Kosten TR. SPECT regional cerebral blood flow in asymptomatic HIV + drug abusers. Soc Neurosci Abstr 15(1):448(#179.11), November,1989. 65. Goodman WK, Price LH, McDougle CJ, Riddle MA, Hoffer PB, Woods SW. SPECT regional blood flow in OCD. Soc Neurosci Abstr 15(1):448(#179.12), November,1989. 66. Price LH, Ricaurte GA, Krystal JH, Heninger GR. Sequelae of 3,4-methylenedioxymethamphetamine (MDMA) in heavy users: Preliminary findings. Soc Neurosci Abstr 15(2):1186(#469.11), November,1989.
25
Lawrence H. Price, MD
67. Seibyl JP, Krystal JH, Price LH, Woods SW, Heninger GR, Charney DS. 5-HT function of the biochemical and behavioral responses to MCPP in healthy subjects and schizophrenics. Soc Neurosci Abstr 15(2):1236(#485.21), November,1989. 68. Seibyl JP, Krystal JH, Price LH, Woods SW, Heninger GR, Charney DS. Neuroendocrine and behavioral responses to MCPP in unmedicated schizophrenics and healthy subjects. Abstr Amer Coll Neuropsychopharm p 122, December,1989. 69. Woods SW, O'Malley SS, Price LH, Krystal JH, Hoffer PB, McDougle CJ, Kosten TR. SPECT regional cerebral blood flow in asymptomatic HIV+ drug abusers. Abstr Amer Coll Neuropsychopharm p 171, December,1989. 70. Goodman WK, Rasmussen SA, Price LH. Type of obsessive-compulsive symptoms and response to clomipramine. Abstr Amer Coll Neuropsychopharm p 175, December,1989. 71. McDougle CJ, Goodman WK, Price LH. Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. Abstr Amer Coll Neuropsychopharm p 176, December,1989. 72. Price LH, Charney DS, Delgado PL, Heninger GR. Fenfluramine augmentation in refractory depression. Abstr Amer Coll Neuropsychopharm p 200, December,1989. 73. Delgado PL, Charney DS, Price LH, Goodman WK, Aghajanian GK, Seibyl J, Heninger GR. Behavioral effects of rapid tryptophan depletion in psychiatric patients and healthy subjects. Abstr Amer Coll Neuropsychopharm p 238, December,1989. 74. Goodman WK, Price LH, Delgado PL, McDougle CJ, Charney DS, Heninger GR. Fluvoxamine and the mechanism of anti-obsessive compulsive disorder action. Proc Amer Psychiatr Assoc p 88, May 1990. 75. Price LH. Treatment of refractory mood disorders: Pharmacological strategies. Proc Amer Psychiatr Assoc p 106, May, 1990. 76. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Charney DS. MCPP effects in schizophrenic patients. Amer Psychiatr Assoc New Research Abstr p 108 (#NR162), May, 1990. 77. Goodman WK, Rasmussen SA, Price LH. Types of symptoms and response to clomipramine in obsessive compulsive disorder. Amer Psychiatr Assoc New Research Abstr p 112 (#NR169), May, 1990. 78. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. Lithium augmentation in fluvoxamine refractory obsessive compulsive disorder Amer Psychiatr Assoc New Research Abstr p 163 (#NR302), May, 1990. 79. Delgado PL, Charney DS, Price LH, Aghajanian GK, Heninger GR. Tryptophan depletion alters mood in depression. Amer Psychiatr Assoc New Research Abstr p 205 (#NR412), May, 1990. 80. Wexler BE, Price LH, Levenson L, Warrenburg S. Physiological aspects of emotion in depression. Amer Psychiatr Assoc New Research Abstr p 206 (#NR414), May, 1990. 81. McDougle CJ, Price LH, Palumbo J, Kleber HD, Heninger GR. Clinical neurobiology of cocaine withdrawal. Amer Psychiatr Assoc New Research Abstr p 258 (#NR551), May, 1990. 82. Woods SW, O'Malley S, Price LH, McDougle CJ, Hoffer PB, Kosten TR. SPECT brain imaging of HIV patients with HMPAO. Amer Psychiatr Assoc New Research Abstr p 267 (#NR569), May, 1990. 83. Price LH, McDougle CJ, Palumbo J, Kosten TR, Kleber HD, Heninger GR. Clinical neurobiology of cocaine withdrawal. Soc Neurosci Abstr 16(1):581(#242.5), November, 1990. 84. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Charney DS. MCPP effects in schizophrenic patients: effects of pharmacotherapy. Soc Neurosci Abstr 16(1):587(#244.6), November, 1990. 85. Delgado PL, Charney DS, Price LH, Aghajanian GK, Heninger GR. Rapid tryptophan depletion reverses antidepressant response and alters mood in depression. Soc Neurosci Abstr 16(2):914(#377.7), November, 1990. 86. Goodman WK, McDougle CJ, Price LH, Charney DS, Heninger GR. Lithium augmentation in fluvoxamine- refractory obsessive compulsive disorder. Soc Neurosci Abstr 16(2):916(#377.21), November, 1990. 87. McDougle CJ, Krystal JH, Woods SW, Price LH, Herbst DA, Heninger GR, Charney DS. The effects of oral idazoxan vs yohimbine in healthy subjects. Soc Neurosci Abstr 16(2):1322(#547.4), November, 1990. 88. Heninger GR, Price LH, Charney DS, Delgado PL. Effects of presynaptic 5HT activation in humans and nonhuman primates. Abstr Amer Coll Neuropsychopharm p 73, December, 1990. 89. Krystal JH, Seibyl JP, Price LH, Woods SW. MCPP effects in schizophrenic patients and healthy subjects. Abstr Amer Coll Neuropsychopharm p 124, December, 1990. 90. Price LH, Delgado PL, Aghajanian GK. Serotonergic function in depression: Neuroendocrine and mood responses to I.V. L-tryptophan in depressive subtypes and health controls. Abstr Amer Coll Neuropsychopharm p 138, December, 1990. 91. Delgado PL, Price LH, Miller HL, Licinio J, Salomon RM, Krystal JH, Aghajanian GK. Serotonin function and the mechanism of antidepressant action. Abstr Amer Coll Neuropsychopharm p 184, December, 1990. 92. Holzer JC, Boyarsky BK, McDougle CJ, Lee N, Price LH, Goodman WK. Differential symptoms in OCD with and without a tic disorder. Abstr Amer Coll Neuropsychopharm p 195, December, 1990.
26
Lawrence H. Price, MD
93. McDougle CJ, Price LH, Palumbo J. Clinical neurobiology of cocaine abstinence. Abstr Amer Coll Neuropsychopharm p 211, December, 1990. 94. Woods SW, Kosten TR, Price LH, McDougle CJ, Smith EO, Hoffer PB. SPECT imaging of asymptomatic HIV+ drug abusers with Tc-99m d,l-HMPAO. J Nucl Med 31:826, 1990. 95. Fayad PB, Price LH, McDougle CJ, Brass LM. Effects of intranasal cocaine on cerebral blood velocities in humans. 5th Internat Symp on Intracran Hemodynamics, February, 1991. 96. McDougle CJ, Krystal JH, Price LH, Heninger GR, Charney DS. Noradrenergic function and ethanol intoxication. Amer Psychiatr Assoc New Research Abstr p 117 (#NR287), May, 1991. 97. McDougle CJ, Goodman WK, Price LH, Holzer JC, McCance-Katz EF, Heninger GR. Buspirone addition in fluvoxamine-refractory OCD. Amer Psychiatr Assoc New Research Abstr p 126 (#NR328), May, 1991. 98. McDougle CJ, Krystal JH, Woods SW, Price LH, Herbst DA, Heninger GR, Charney DS. Oral idazoxan vs yohimbine in healthy subjects. Amer Psychiatr Assoc New Research Abstr p 127 (#NR329), May, 1991. 99. Holzer JC, Price LH, McDougle CJ, Boyarsky BK, Goodman WK. Symptoms in OCD with and without a tic disorder. Amer Psychiatr Assoc New Research Abstr p 134 (#NR358), May, 1991. 100. McDougle CJ, Calvocoressi L, Seibyl JP, Krystal JH, Heninger GR, Price LH. Neurobiology of early-life trauma in depression. Amer Psychiatr Assoc New Research Abstr p 203 (#NR648), May, 1991. 101. McCance-Katz E, Price LH, Charney DS, Heninger GR. Serotonergic function in lithium augmentation. Amer Psychiatr Assoc New Research Abstr p 204 (#NR651), May, 1991. 102. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of OCD. Proc Amer Psychiatr Assoc p 32, May, 1991. 103. Goodman WK, McDougle CJ, Price LH, Charney DS, Heninger GR. Serotonin reuptake inhibitors in OCD. Proc Amer Psychiatr Assoc pp 144-145, May, 1991. 104. McDougle CJ, Goodman WK, Price LH, Heninger GR. Medication approaches to treatment-resistant OCD. Proc Amer Psychiatr Assoc p 145, May, 1991. 105. McCance-Katz EF, Price LH, McDougle CJ, Marek GJ, Kosten TR, Jatlow P. Cocaethylene formation following sequential administration of cocaine and ethanol to humans: Pharmacological, physiological, and behavioral studies. Soc Neurosci Abstr 17(1):890(#349.1), November, 1991. 106. McDougle CJ, Krystal JH, Price LH, Heninger GR, Charney DS. Noradrenergic function and ethanol intoxication. Soc Neurosci Abstr 17(2):1420(#564.13), November, 1991. 107. Delgado PL, Miller HL, Salomon RS, Licinio J, Price LH, Heninger GR, Krystal JH, Charney DS. Serotonin function and the mechanism of antidepressant action. Soc Neurosci Abstr 17(2):1436(#569.9), November, 1991. 108. Malison RT, Price LH, Delgado PL, Charney DS, Heninger GR. Enhanced cortisol response to fenfluramine in major depression. Soc Neurosci Abstr 17(2):1469( #580.12), November, 1991. 109. Price LH, Malison R, McCance-Katz EF, McDougle, CJ, Owen K, Delgado PL, Heninger GR. Neuroendocrine and mood responses to I.V. M-CPP during tryptophan depletion in depressed patients. Abstr Amer Coll Neuropsychopharm p 121, December, 1991. 110. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Efficacy of haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind placebo-controlled study. Abstr Amer Coll Neuropsychopharm p 183, December, 1991. 111. Fayad PB, Price LH, McDougle CJ, Pavalkis FJ, Brass LM. Acute hemodynamic effects of intranasal cocaine on the cerebral circulation. 6th Internat Symp on Cerebral Hemodynamics January, 1992 (published in Stroke 23:159, 1992). 112. Fayad PB, Price LH, McDougle CJ, Pavalkis FJ, Brass LM. Acute hemodynamic effects of intranasal cocaine on the cerebral and cardiovascular systems. 17th Internat Joint Conf on Stroke and Cerebr Circulation January, 1992 (published in Stroke 23:457, 1992). 113. Delgado PL, Salomon RS, Licinio J, Miller HL, Price LH, Heninger GR, Aghajanian GK, Charney DS. Monoamines and the mechanism of antidepressant action. Abstr Amer Coll Neuropsychopharm p 228, December, 1991. 114. McCance-Katz EF, Price LH, McDougle CJ, Black JE, Kosten TR, Jatlow PI. Cocaine-ethanol and cocaethylene: Clinical effects. Amer Psychiatr Assoc New Research Abstr p 71 (#NR100), May, 1992. 115. Barr LC, Price LH, McDougle CJ, Delgado PL, Goodman WK. Acute tryptophan depletion in drug-remitted OCD. Amer Psychiatr Assoc New Research Abstr p 81 (#NR141), May, 1992. 116. Black JE, Goodman WK, Boyarsky BK, Price LH. Compulsive behaviors and cocaine. Amer Psychiatr Assoc New Research Abstr p 91 (#NR180), May, 1992. 117. Naylor ST, McDougle CJ, Goodman WK, Volkmar FR, Cohen DJ, Hawkins KA, Price LH. OCD symptoms in adults with autistic disorder. Amer Psychiatr Assoc New Research Abstr p 96 (#NR200), May, 1992. 118. Price LH, McCance-Katz EF, Marek KL. Serotonin in Parkinson's disease and depression. Amer Psychiatr Assoc New Research Abstr p 122 (#NR305), May, 1992.
27
Lawrence H. Price, MD
119. Goodman WK, McDougle CJ, Price LH, Barr LC, Heninger GR. Oral and parenteral MCPP in 12 patients with OCD. Amer Psychiatr Assoc New Research Abstr p 171 (#NR509), May, 1992. 120. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine- refractory OCD. Amer Psychiatr Assoc New Research Abstr p 172 (#NR513), May, 1992. 121. Fayad PB, Price LH, McDougle CJ, Pavalkis FJ, Brass LM. Acute effects of cocaine on cerebral hemodynamics and cardiovascular system: A study in humans. 2nd World Congr of Stroke September, 1992 (published in J Stroke Cerebrovasc Dis 2(Suppl 1):S79, 1992). 122. Barr LC, Price LH, McDougle CJ, Delgado PL, Goodman WK. Effects of acute tryptophan depletion in drug- remitted obsessive-compulsive disorder patients. Soc Neurosci Abstr 18(1):3(#7.3), November, 1992. 123. Delgado PL, Miller HL, Salomon RM, Licinio J, Price LH, Heninger GR, Charney DS. The mechanism of antidepressant action in depression. Soc Neurosci Abstr 18(1):727(#303.15), November, 1992. 124. McDougle CJ, Price LH, Kosten TR, Black J, Malison RT, Zimmermann RC, Kleber HD. Noradrenergic responsivity during cocaine abstinence. Soc Neurosci Abstr 18(2):1239(#516.10), November, 1992. 125. Redmond DE Jr, Marek KL, Leranth C, Robbins RJ, Naftolin F, Roth RH, Gjedde A, Bunney BS, Price LH, Sass KJ, Elsworth JD, Makuch R, Gulanski BI, Serrano C, Gerber A, Farhi A, Spencer DD. The prospects for dopamine neuroblasts as treatment for Parkinson's disease. Abstr Amer Coll Neuropsychopharm p 41, December, 1992. 126. Woods SW, Rosen MI, Price LH, Pearsall HR, Gallager DW, Charney DS, Heninger GR, Kosten TR. Rapid benzodiazepine detoxification using flumazenil. Abstr Amer Coll Neuropsychopharm p 134, December, 1992. 127. Goddard AW, Goodman WK, Woods SW, Heninger GR, Charney DS, Price LH. Effects of tryptophan depletion on panic anxiety. Abstr Amer Coll Neuropsychopharm p 150, December, 1992. 128. Barr LC, Price LH, McDougle CJ, Delgado PL, Goodman WK. Acute tryptophan depletion exacerbates depressive, but not obsessive compulsive, symptoms in drug-remitted obsessive-compulsive disorder patients. Abstr Amer Coll Neuropsychopharm p 154, December, 1992. 129. McDougle CJ, Price LH, Kosten TR, Black J, Malison RT, Zimmermann RC, Kleber HD. Noradrenergic responsivity during cocaine abstinence. Abstr Amer Coll Neuropsychopharm p 226, December, 1992. 130. Goodman WK, McDougle CJ, Barr LC, Price LH. Biological approaches to the treatment-refractory patient. First International Obsessive Compulsive Disorder Conference, Capri, Italy, March 12-13, 1993. 131. Goodman WK, McDougle CJ, Price, LH. Pharmacotherapy of obsessive compulsive disorder. First International Obsessive Compulsive Disorder Conference, Capri, Italy, March 12-13, 1993. 132. Aronson SC, Black JE, McDougle CJ, Scanley E, Kosten TR, Heninger GR, Price LH. Serotonin and cocaine effects in humans. Amer Psychiatr Assoc New Research Abstr p 64 (#NR19), May, 1993. 133. Price LH. Lithium augmentation in refractory depression. Proc Amer Psychiatr Assoc p 229, May, 1993. 134. Barr LC, Aronson SC, Anand A, Price LH, Goodman WK. Clozapine in treatment resistant obsessive compulsive disorder. Soc Neurosci Abstr 19(1):383(#158.6), November, 1993. 135. Goddard AW, Goodman WK, Woods SW, Charney DS, Heninger GR, Price LH. Effects of tryptophan depletion on panic anxiety. Soc Neurosci Abstr 19(1):591(#244.2), November, 1993. 136. Marek KL, Spencer DD, Naftolin F, Robbins RJ, Farhi AE, Serrano CC, Vollmer TL, Gerber A, Levy L, Leranth C, Roth RH, Bunney BS, Sass KJ, Price LH. Long-term effects of human fetal mesencephalic tissue implantation in Parkinsonian patients. Soc Neurosci Abstr 19(1):630(#264.4), November, 1993. 137. McDougle CJ, Aronson SC, Black JE, Scanley BE, Kosten TR, Heninger GR, Price LH. Serotonin and cocaine effect in humans. Soc Neurosci Abstr 19(3):1864(#762.6), November, 1993. 138. Rosen MI, Price LH, Kosten TR. Serotonin and cocaine's clinical effects. Abstr Amer Coll Neuropsychopharm, p. 29, December, 1993. 139. Barr LC, Goodman WK, Heninger GR, Price LH. Vulnerability to the depressant effect of tryptophan depletion not conferred solely by antidepressant administration. Abstr Amer Coll Neuropsychopharm, p. 107, December, 1993. 140. Goddard AW, Charney DS, Sholomskas DE, Augeri FM, Walton KE, Woods SW, Heninger GR, Price LH, Goodman WK. Effects of tryptophan depletion on anxiety responses to yohimbine in panic disorder. Abstr Amer Coll Neuropsychopharm, p. 107, December, 1993. 141. McDougle CJ, Aronson SC, Black JE, Scanley BE, Kosten TR, Heninger GR, Price LH. Serotonin and cocaine effect in humans. Abstr Amer Coll Neuropsychopharm, p. 170, December, 1993. 142. Chappell PB, Leckman JF, Goodman WK, Bissette G, Pauls DL, Anderson GM, Riddle MA, Scahill LD, Price LH. McDougle CJ, Barr LC, Cohen DJ. Elevated levels of CSF CRF in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Abstr Amer Coll Neuropsychopharm, p. 195, December, 1993. 143. Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, Anderson GM, Riddle MA, McSwiggan- Hardin M, McDougle CJ, Barr LC, Cohen DJ. Elevated levels of CSF oxytocin in obsessive compulsive disorder:
28
Lawrence H. Price, MD
Comparison with Tourette's syndrome and healthy controls. Abstr Amer Coll Neuropsychopharm, p. 195, December, 1993. 144. McCance-Katz EF, Price LH, Kosten TR, Hameedi F, Rosen MI, Jatlow PI. Pharmacology, physiology and behavioral effects of cocaethylene in humans. Abstr Amer Coll Neuropsychopharm, p. 237, December, 1993. 145. Goodman WK, McDougle CJ, Barr LC, Leckman JF, Price LH. Serotonin/dopamine interaction in Tourette's syndrome related OCD. In Symposium 40, "The Neurobiology and Treatment of Human Anxiety: Recent Advances." Proc Amer Psychiatric Assoc, p. 88, May, 1994. 146. Hameedi F, Rosen MI, Price LH, Farren CK, Woods SW, Kosten TR. Serotonergic function during acute and chronic cocaine abstinence. Amer Psychiatr Assoc New Research Abstr p 163 (#NR407), May, 1994. 147. McCance-Katz EF, Price LH, Kosten TR, Jatlow PI. Cocaethylene effects in humans. Amer Psychiatr Assoc New Research Abstr p 164 (#NR412), May, 1994. 148. Barr LC, Goodman WK, Anand A, Price LH. Desipramine augmentation of selective serotonin reuptake inhibitor treatment of refractory OCD. Amer Psychiatr Assoc New Research Abstr p 213 (#NR602), May, 1994. 149. Barr LC, Goodman WK, Heninger GR, Price LH. Effects of tryptophan depletion on mood during fluoxetine treatment of healthy subjects. Amer Psychiatr Assoc New Research Abstr p 213 (#NR603), May, 1994. 150. Goddard AW, Charney DS, Sholomskas DE, Augeri FM, Walton KE, Woods SW, Heninger GR, Price LH, Goodman WK. Effects of tryptophan depletion on anxiety responses to yohimbine in panic disorder. Soc Neurosci Abstr 20(1):379(#162.14), November, 1994. 151. Cappiello A, McDougle CJ, Delgado PL, Malison RT, Charney DS, Heninger GR, Price LH. Lithium and desipramine for the treatment of major depression: Is the combination superior to desipramine alone? Soc Neurosci Abstr 20(1):384(#164.10), November, 1994. 152. McDougle CJ, Naylor ST, Volkmar FR, Cohen DJ, Heninger GR, Price LH. A double-blind, placebo-controlled investigation of fluvoxamine in adults with autism. Soc Neurosci Abstr 20(1):396(#168.12), November, 1994. 153. Barr LC, Bennett A, D'Souza DC, Price LH, Krystal JH. Evaluation of dose-related effects of D-cycloserine in unmedicated obsessive compulsive disorder patients. Soc Neurosci Abstr 20(2):1564(#641.7), November, 1994. 154. McDougle CJ, Naylor ST, Volkmar FR, Cohen DJ, Heninger GR, Price LH. A double-blind, placebo-controlled investigation of fluvoxamine in adults with autism. Abstr Amer Coll Neuropsychopharm, p. 90, December, 1994. 155. Price LH, Cappiello A, McDougle CJ, Delgado PL, Malison RT, Charney DS, Heninger GR. Lithium+desipramine vs. desipramine alone in the treatment of major depression: A controlled study. Abstr Amer Coll Neuropsychopharm, p. 103, December, 1994. 156. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorder. Amer Psychiatr Assoc New Research Abstr p. 74(#NR76), May, 1995. 157. Cappiello AC, McDougle CJ, Malison RT, Heninger GR, Price LH. Yohimbine augmentation of fluvoxamine in refractory depression: A preliminary, single-blind study. Amer Psychiatr Assoc New Research Abstr p. 80(#NR95), May, 1995. 158. Epperson CN, McDougle CJ, Brown RM, Leckman JF, Goodman WK, Price LH. OCD during pregnancy and the puerperium. Amer Psychiatr Assoc New Research Abstr p. 84(#NR112), May, 1995. 159. Brown RM, McDougle CJ, Epperson CN, Wasylink S, Goodman WK, Price LH. OCD and suicide: A systematic investigation. Amer Psychiatr Assoc New Research Abstr p. 85(#NR116), May, 1995. 160. Pelton GH, Cappiello AC, McDougle CJ, Malison RT, Kosten TR, Price LH. Reserpine/cocaine interactions in cocaine addicts. Amer Psychiatr Assoc New Research Abstr p. 97(#NR161), May , 1995. 161. Price LH, Cappiello AC, McDougle CJ, Malison RT, Charney DS, Heninger GR. Lithium plus desipramine versus desipramine alone in the treatment of major depression: A controlled study. Amer Psychiatr Assoc New Research Abstr p 132(#NR284), May, 1995. 162. Malison RT, McDougle CJ, Van Dyck C, Scahill, L, Baldwin RM, Seibyl JP, Price LH, Leckman JF, Innis RB. [123I]B-CT SPECT imaging demonstrates increased striatal dopamine transporter binding in Tourette's syndrome. Amer Psychiatr Assoc New Research Abstr p. 196(#NR527), May, 1995. 163. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian, GK, Heninger GR, Price LH. Acute tryptophan depletion in adults with autism. Amer Psychiatr Assoc New Research Abstr p. 197(#NR531), May , 1995. 164. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian, GK, Heninger GR, Price LH. Acute tryptophan depletion in adults with autism. Soc Neurosci Abstr 21(1):735(#293.14), November, 1995. 165. Pelton GH, Price LH, Heninger GR. Epinephrine stimulates increased IL-6 blood levels in healthy human subjects. Soc Neurosci Abstr 21(2):1502(#590.8), November, 1995. 166. Cappiello A, Malison RT, McDougle CJ, Vegso S, Charney DS, Heninger GR, Price LH. Seasonal variation in neuroendocrine and mood response to L-tryptophan infusion in depressed patients and healthy subjects. Soc Neurosci Abstr 21(3):2057(#809.6), November, 1995.
29
Lawrence H. Price, MD
167. Chappell PB, Anderson GM, Goodman WK, Price LH, Hall LM, Cohen DJ, Leckman JF. Kynurenine pathway metabolites in cerebrospinal fluid and plasma of Tourette Syndrome Patients. Soc Neurosci Abstr 21(3):1733(#677.9), November, 1995. 168. Woods SW, Rosen ML, Price LH, Pearsall HR, Hameedi FA, Gallager DW, Charney DS, Heninger GR, Kosten TR. Effects of flumazenil benzodiazepine dependence in man. Soc Neurosci Abstr 21(3):2098(#824.13), November, 1995. 169. Pelton GH, Price LH, Heninger GR. Epinephrine stimulates increased IL-6 blood levels in major depression. Abstr Amer Coll Neuropsychopharm, p. 122, December, 1995. 170. Price LH, Pelton GH, Cappiello A, McDougle CJ, Malison RT, Jatlow P, Kosten TR, Heninger GR. Attenuation of cocaine effects by reserpine in cocaine-dependent humans. Abstr Amer Coll Neuropsychopharm, p. 193, December, 1995. 171. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Acute tryptophan depletion in adults with autism. Abstr Amer Coll Neuropsychopharm, p. 206, December, 1995. 172. Malison RT, Best S, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Price LH, Kosten TR, Innis RB. Persistently elevated striatal [123I]ß-CIT binding in cocaine addicts during sustained drug abstinence. Abstr Amer Coll Neuropsychopharm, p. 231, December, 1995. 173. Epperson CN, McDougle CJ, Ward-O'Brien D, Price LH. A controlled study of sertraline versus placebo in the treatment of postpartum depression: Preliminary findings. Soc Biol Psychiatry Ann Mtg, New York, NY, May, 1996. 174. Epperson CN, McDougle CJ, Ward-O'Brien D, Price LH. A controlled study of antidepressant treatment of postpartum depression. Amer Psychiatr Assoc New Research Abstr p. 74 (#NR28), May, 1996. 175. Kirwin PD, McDougle CJ, Anderson GM, Heninger GR, Leckman JF, Price LH. Diurnal variation in CSF serotonin concentrations in healthy humans. Amer Psychiatr Assoc New Research Abstr p. 75 (#NR34), May, 1996. 176. Pelton GH, Price LH, Heninger GR. Epinephrine increases plasma interleukin-6 in major depression. Amer Psychiatr Assoc New Research Abstr p. 118 (#NR187), May, 1996. 177. Epperson CN, Ward-O'Brien D, Price LH, McDougle CJ. A double-blind study of sertraline versus placebo in the treatment of postpartum depression: preliminary findings. Soc Neurosci Abstr 22(1):179(#76.3), November, 1996. 178. Kirwin PD, McDougle CJ, Anderson GM, Heninger GR, Geracioti PB, Chappell JF, Leckman JF, Price LH. Diurnal variation in CSF serotonin concentrations in healthy humans. Soc Neurosci Abstr 22(1):604(#242.4), November, 1996. 179. Price LH, Pelton GH, McDougle CJ, Malison RT, Jatlow P, Carpenter L, Kirwin PD, Ward-O'Brien D, Heninger GR. Effects of acute pretreatment with risperidone on responses to cocaine in cocaine-dependent humans. Soc Neurosci Abstr 22(2):933(#365.7), November, 1996. 180. Pelton GH, Price LH, Malison RT, Heninger GR. Epinephrine stimulates IL-6 release in major depression and healthy controls. Soc Neurosci Abstr 22(2):1352(#536.14), November, 1996. 181. Heninger GR, Price LH, Malison RT, Pelton GH. Neural-immune abnormalities in depressed patients and healthy controls. Soc Neurosci Abstr 22(2):1456(#578.10), November, 1996. 182. Berman RM, Delgado PL, Miller HL, Price LH, Heninger GR, Charney DS. Correlates of depressive relapse in medicated depressed subjects undergoing acute tryptophan depletion. Soc Neurosci Abstr 22(3):2066(#811.10), November, 1996. 183. Price LH, Cappiello A, Malison RT, McDougle CJ, Pelton GH, Heninger GR. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects. Abstr Amer Coll Neuropsychopharm, p. 156, December, 1996. 184. Epperson CN, Ward-O'Brien D, Price LH, McDougle CJ. A double-blind study of sertraline versus placebo in the treatment of postpartum depression: preliminary findings. Abstr Amer Coll Neuropsychopharm, p. 172, December, 1996. 185. Pelton GH, Price LH, McDougle CJ, Malison RT, Heninger GR. Neuroendocrine responses to immune stimulants in major depression. Abstr Amer Coll Neuropsychopharm, p. 233, December, 1996. 186. Cappiello A, Sernyak M, Malison RT, McDougle CJ, Heninger GR, Price LH. Effects of acute tryptophan depletion in lithium remitted manic patients. Abstr Amer Coll Neuropsychopharm, p. 238, December, 1996. 187. Cubells J, Anderson GM, Price LH, Kobayashi K, Nagatsu T, Charney DS, Heninger GR, Gelernter J. Dopamine b- hydroxylase: genotype and biochemical phenotype. Abstr Amer Coll Neuropsychopharm, p. 272, December, 1996. 188. Carpenter LL, Anderson G, McDougle CJ, Kirwin PD, Price LH, Heninger GR. Tryptophan depletion during continuous sampling via indwelling lumbar catheter in healthy human subjects. Amer Psychiatr Assoc New Research Abstr p. 85 (#NR72), May, 1997. 189. Pelton GH, McDougle CJ, Carpenter LL, Anderson GM, Gudin JA, Price LH, Malison RT, Kirwin P, Heninger GR. Cerebrospinal fluid levels of interleukin-1 and interleukin-6 increase after intravenous lipopolysaccharide in healthy humans. Soc Neurosci Abstr 23(1):992(#393.5), October, 1997.
30
Lawrence H. Price, MD
190. Carpenter LL, Anderson G, Pelton G, Gudin JA, Kirwin PD, Price LH, Heninger GR, McDougle CJ. Tryptophan delpetion during continuous CSF sampling via indwelling lumbar catheter in healthy human subjects. Soc Neurosci Abstr 23(2):1220(#483.16), October, 1997. 191. Malison RT, Pelton G, Carpenter LL, Sanacora G, Haroon E, Potenza M, Berman R, Baldwin RM, Seibyl JS, Price LH, Innis RB, Charney DS. Reduced midbrain serotonin transporter binding in depressed healthy subjects as measured by [123]b-CIT SPECT. Soc Neurosci Abstr 23(2):1220(#483.17), October, 1997. 192. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein and obsessive compulsive disorder. Amer Soc Hum Gen Ann Mtg, October, 1997. 193. Price LH, Pelton GH, McDougle CJ, Malison RT, Jatlow P, Carpenter LL, Kirwin PD, O’Brien DW, Nadim H, Heninger GR. Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts. Abstr Amer Coll Neuropsychopharm p. 208, December, 1997. 194. Malison RT, Price LH, Berman R, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced midbrain serotonin transporter binding in major depression as measured by [123I]ß-CIT SPECT. Soc Nucl Med Abstr 1998. 195. Carpenter LL, Jocic Z, Hall J, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. Amer Psychiatr Assoc New Research Abstr p. 265(#NR728), May, 1998. 196. Price LH, Malison RT, Cappiello A, McDougle CJ. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy controls. XXIst Coll Internat Neuro-Psychopharm Abstr p.105 (ST0202), July, 1998. 197. Kanes SJ, Sawires A, Kranzler R, Price LH, Berman R, Ichinose H, Nagatsu T, Wantroba AM, Rosenheck R, Kramer J, Charney D, Gelernter J. COMT: Population and association studies of a functional polymorphism. Soc Neurosci Abstr 25(2):2094(#838.2), October, 1999. 198. Carpenter LL, Anderson GM, Yasmin S, Keller MB, Chappell PB, Price LH. Acute changes in CSF 5-HIAA following oral paroxetine challenge in healthy humans. Abstr Amer Coll Neuropsychopharm p. 210, December, 1998. 199. Price LH, Carpenter LL, Jocic Z, Rasmussen SA. Mirtazapine augmentation in the treatment of refractory depression. Abstr Amer Coll Neuropsychopharm p. 312, December, 1998. 200. Carpenter LL, Anderson GM, Yasmin S, Keller MB, Chappell PB, Price LH. Acute changes in CSF 5-HIAA following oral paroxetine challenge in healthy humans. Amer Psychiatr Assoc New Research Abstr May, 1999. 201. Phillips KA, Grant J, Albertini RS, Stout R, Price LH. Retrospective follow-up study of body dysmorphic disorder. Amer Psychiatr Assoc New Research Abstr #NR312, May, 1999. 202. Phillips KA, Grant J, Albertini RS, Stout R, Price LH. Retrospective follow-up study of body dysmorphic disorder. NCDEU Ann Mtg Abstr p. 185, June, 1999. 203. Phillips KA, Grant J, Albertini RS, Stout R, Price LH. Retrospective follow-up study of body dysmorphic disorder. Abstr Amer Coll Neuropsychopharm p. 172, December, 1999. 204. Zimolo Z, Pelton GH, McDougle CJ, Price LH, Heninger GR. Serum leptin changes after lipopolysaccharide-induced stress in humans. Abstr Amer Coll Neuropsychopharm p. 289, December, 1999. 205. Cubells JF, Price LH, Meyers B, Anderson GM, Zabetian CP, Malison RT, Alexopoulous G, Sanacora G, Nelson JC, Kirwin P, Gelernter J. Genotype-controlled analysis of plasma dopamine b-hydroxylase activity in unipolar psychotic depression. Soc Neurosci Abstr 26(1):1161(#436.1), October, 2000. 206. Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, Price LH. Adjunctive gabapentin in treatment-resistant depression. Amer Psychiatr Assoc New Research Abstr #NR153, May, 2000. 207. Carpenter LL, Yasmin S, Price LH. A double-blind placebo-controlled study of mirtazapine augmentation for refractory depression: preliminary findings. NCDEU Ann Mtg Abstr June, 2000. 208. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory major depression: preliminary findings. Inst on Psychiatr Servs Syllab and Procdngs pp. 145-146, October, 2000. 209. Phillips KA, Rauch S, Deckersbach T, Rasmussen SA, Savage C, Albertini RS, Wilhelm S, Grant J, Price LH, Baer L, Jenike M. BDD: Phenomenology, course, treatment, neuropsychology, and structural imaging. Abstr Amer Coll Neuropsychopharm p. 61, December, 2000. 210. Price LH, Gagne GG, Furman MJ, Carpenter LL. The efficacy of continuation electroconvulsive therapy in chronically depressed patients. Abstr Amer Coll Neuropsychopharm p. 145, December, 2000. 211. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Abstr Amer Coll Neuropsychopharm p. 154, December, 2000. 212. Renazco MA, Haggarty R, Price LH. Psychotic depression: Differences between delusional and nondelusional forms. Amer Psychiatr Assoc New Research Abstr #NR80, May, 2001.
31
Lawrence H. Price, MD
213. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Amer Psychiatr Assoc New Research Abstr #NR505, May, 2001. 214. Carpenter LL, Kirwin PD, Pelton GH, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Tryptophan depletion increases CSF corticotropin releasing factor in healthy adults humans. Abstr Amer Coll Neuropsychopharm p. 137, December, 2001. 215. Carpenter LL, Kirwin PD, Pelton GH, Heninger GR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Relationship between CSF corticotropin releasing factor and perceived early life stress in depressed patients and healthy controls. Abstr Amer Coll Neuropsychopharm p. 137, December, 2001. 216. Carpenter LL, Pelton GH, Heninger GR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Relationship between CSF Corticotropin Releasing Factor and Perceived Early Life Stress in Depressed Patients and Healthy Controls. Amer Psychopatholog Assoc Ann Mtg Abstr, March, 2002. 217. Carpenter LL, Pelton GH, Heninger GR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. CSF Corticotropin Releasing Factor and Perceived Early Life Stress in Depressed Patients and Healthy Controls. Amer Psychiatr Assoc New Research Abstr #480, May, 2002. 218. Tyrka AR, Carpenter LL, Brown RA, Strong DR, Kahler CW, Anderson GM, Price LH. Early-life stress and response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Abstr Amer Coll Neuropsychopharm p. 137, December, 2002. 219. Carpenter LL, Moreno F, Kling MA, Owens M, Anderson G, Price LH. Effects of VNS on CSF components in depressed patients. Abstr Amer Coll Neuropsychopharm p. 141, December, 2002. 220. Carpenter LL, Tyrka AR, Schecter J, Haggarty R, Price LH. Tiagabine for major depression with anxiety. Soc Biol Psychiatry Ann Mtg, #107, May, 2003. 221. Tyrka AR, Carpenter LL, Brown RA, Strong DR, Kahler CW, Anderson GM, Price LH. Early-life stress and response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Soc Biol Psychiatry Ann Mtg, #145, May, 2003. 222. Tyrka AR, Carpenter LL, Brown RA, Strong DR, Kahler CW, Anderson GM, Price LH. Early-life stress and pituitary-adrenal function in healthy adults. Amer Psychiatr Assoc New Research Abstr #NR61, May, 2003. 223. Carpenter LL, Tyrka AR, Schecter JM, Haggarty R, Price LH. Tiagabine for MDD with anxiety. Amer Psychiatr Assoc New Research Abstr #NR501, May, 2003. 224. Price LH, Weisler RS, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: A randomized, double-blind placebo-controlled trial. Abstr Amer Coll Neuropsychopharm p. 160, December, 2003. 225. Kling MA, Carpenter LL, Moreno F, Price LH, Owens MJ, Kinkead B, Nemeroff CB. Decreased cerebrospinal fluid (CSF) concentrations of substance P (SP) in medicated patients with treatment-resistant major depression (TRD). Abstr Amer Coll Neuropsychopharm p. 161, December, 2003. 226. Carpenter LL, Price LH, Kinkead B, Cassell T, Sanacora G, Owens MJ, Nemeroff CB. Elevated cerebrospinal fluid concentration of substance P in major depression. Abstr Amer Coll Neuropsychopharm p. 215, December, 2003. 227. Tyrka AR, Carpenter LL, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Price LH. CSF corticotropin- releasing factor increases during tryptophan depletion. Amer Psychiatr Assoc New Research Abstr #NR78, May, 2004. 228. Milosavljevic N, Schecter JM, Price LH, Carpenter LL. Antidepressant augmentation with open-label atomoxetine. Amer Psychiatr Assoc New Research Abstr #NR138, May, 2004. 229. Carpenter LL, Price LH, Kinkead B, Cassell T, Sanacora G, Owens MJ, Nemeroff CB. Elevated CSF concentration of substance P in major depression. Amer Psychiatr Assoc New Research Abstr #NR786, May, 2004. 230. Greenberg BD, Price LH, Friehs G, Malone D, Rezai AR, Shapira NA, Foote KD, Okun MA, Rauch SL, Dougherty D, Noren G, Malloy PF, Salloway S, Marsland R, Tyrka A, Carpenter L, Goodman W, Rasmussen SA. Deep brain stimulation in intractable OCD, and preliminary results in intractable depression. NCDEU Ann Mtg Abstr p. 44, June, 2004. 231. Carpenter LL, Milosavljevic N, Schecter JM, Price LH. Open-label antidepressant augmentation with atomoxetine. Abstr Amer Coll Neuropsychopharm #74, December, 2004. 232. Greenberg BD, Friehs G, Carpenter L, Tyrka A, Malone D, Rezai A, Shapira N, Foote K, Okun M, Goodman W, Rasmussen S, Price LH. Deep brain stimulation: Clinical findings in intractable depression and OCD. Abstr Amer Coll Neuropsychopharm #468, December, 2004. 233. Tyrka AR, Carpenter LL, Mello AA, Mello MF, Gagne GG, Price LH. Temperament and pituitary-adrenal response to the DEX/CRH test in healthy adults. Abstr Amer Coll Neuropsychopharm #88, December, 2004. 234. Tyrka AR, Carpenter LL, Feijo de Mello AA, Feijo de Mello M, Gagne GG, Grover KE, Anderson GM, Price LH. Temperament and pituitary-adrenal response to the DEX/CRH test in healthy adults. Soc Biol Psychiatry Ann Mtg #690, May, 2005.
32
Lawrence H. Price, MD
235. Friehs G, Carpenter L, Tyrka A, Malone D, Rezai AR, Shapira NA, Foote K, Okun M, Rauch SL, Goodman WK, Rasmussen SA, Price LH, Greenberg BD. Deep brain stimulation in intractable OCD, and preliminary results in intractable depression. 10th Ann Conf Internat FES Soc p. 44, July, 2005. 236. Tyrka AR, Carpenter LL, Wier L, Feijo de Mello AA, Feijo de Mello M, Gagne GG, Grover KE, Anderson GM, Price LH. Temperament and response to the DEX/CRH test in healthy adults. Internat Soc Psychoneuroendocrin Ann Mtg, September, 2005. 237. Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Gagne GG, Mello AF, Mello MF, Gagne GG, Anderson GM, Price LH. Temperament and response to the DEX/CRH test in healthy adults. Internat Soc Psychoneuroendocrin Ann Mtg, September, 2005. 238. Carpenter LL, Tyrka AR, Carvalho JP, Wier L, Gagne GG, Mello AF, Mello, MF, Anderson GM, Price LH. Decreased cortisol response to the Trier Social Stress Test in healthy adults with significant childhood adversity. Abstr Amer Coll Neuropsychopharm S153 #28, December, 2005. 239. Tyrka AR, Carpenter LL, Anderson GM, Price LH. Inhibited temperament and HPA axis function in healthy adults. Abstr Amer Coll Neuropsychopharm S242 #86, December, 2005. 240. Kelly MM, Carpenter LL, Tyrka AR, Anderson GA, Price LH. Parental bonding and stress reactivity: The mediating effects of trait anxiety. Anx Disord Assoc Amer Ann Mtg #25, March, 2006. 241. Tyrka AR, Carpenter LL, Carvalho JP, Wier LM, Gagne GG, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH. Attenuated cortisol and ACTH responses to the Trier Social Stress Test in healthy adults with a history of childhood maltreatment. Soc Biol Psychiatry Ann Mtg #244, May, 2006. 242. Kelly MM, Tyrka AR, Anderson GM, Price LH, Carpenter LL. Sex differences in emotional and physiological responses to the Trier Social Stress Test. Assoc Behav Cognitive Ther Ann Mtg #5B6, November, 2006. 243. Hitsman B, Niaura R, Shadel WG, Britt DM, Price LH. Effect of varenicline on cue-provoked cigarette craving and acute nicotine withdrawal. Abstr Amer Coll Neuropsychopharm S75 #15, December, 2006. 244. Tyrka AR, Carpenter LL, Gelernter J, Kelly MM, Price LH. COMT genetic variation and depression: Gene- environment interaction and HPA axis correlates. Abstr Amer Coll Neuropsychopharm S96 #65, December, 2006. 245. Brown RA, Strong DR, Miller IW, Kahler CW, Niaura R, Price LH. Efficacy of sequential vs concurrent use of fluoxetine in smoking cessation for elevated depressive symptom smokers. Soc Res Nicotine Tobacco Ann Mtg #SYM8D, February, 2007. 246. Niaura R, Hitsman B, Shadel WG, Britt DM, Price LH. Effect of varenicline on cue-provoked cigarette craving and acute nicotine withdrawal. Soc Res Nicotine Tobacco Ann Mtg #PA 11-3, February, 2007. 247. Carpenter LL, Tyrka AR, Anderson GA, Price LH. Childhood maltreatment, female sex, and perceived stress burden: Significant determinants of cortisol response to the DEX/CRH test in healthy adults. Soc Biol Psychiatry Ann Mtg #217, May, 2007. 248. Tyrka AR, Wier L, Price LH, Anderson GA, Carpenter LL. Childhood parental loss and cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Soc Biol Psychiatry Ann Mtg #711, May, 2007. 249. Price LH, Tyrka AR, Carpenter LL, Gelernter J, Kelly MM. COMT genetic variation and depression: Gene- environment interaction and HPA axis correlates. Abstr Soc Biol Psychiatry Ann Mtg #745, May, 2007. 250. Niaura R, Hitsman B, Shadel WG, Britt DM, Di Benedetti DB, Price LH. Efecto de vareniclina sobre el craving y el síndrome de abstinecia tras un estímulo positivo con cigarrillos. VII Congreso Nacional de Prevención y Tratamiento del Tabaquismo, Castellón, Spain, October, 2007. 251. Kelly MM, Tyrka AR, Price LH, Carpenter LL. Sex differences in the use of coping strategies: Predictors of anxiety and depressive symptoms. Assoc Behav Cognitive Ther Ann Mtg #11B8, November, 2007. 252. Dougherty DD, Malone D, Carpenter L, Tyrka A, Friehs G, Rezai A, Eskander E, Machado A, Kubu C, Malloy P, Salloway S, Rauch SL, Price L, Rasmussen S, Greenberg B. Long-term outcomes of ventral capsule/ventral striatum DBS for highly treatment-resistant depression. Abstr Amer Coll Neuropsychopharm #I.47, December, 2007. 253. Tyrka AR, Carpenter LL, Gelernter J, Price LH. Serotonin transporter polymorphism, childhood maltreatment, and cortisol response to the Dex/CRH test in healthy adults: Preliminary findings. Abstr Amer Coll Neuropsychopharm #I.89, December, 2007. 254. Carpenter LL, Tyrka AR, Anderson GM, Wilkinson CW, Price LH. Depression, childhood maltreatment, and gender are significant determinants of cortisol response to the Dex/CRH test. Abstr Amer Coll Neuropsychopharm #I.107, December, 2007. 255. Malone DA, Dougherty DD, Rezai A., Carpenter LL, Friehs GM, Eskander E, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis J, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Amer Psychiatr Assoc Ann Mtg, May, 2008.
33
Lawrence H. Price, MD
256. Tyrka AR, Carpenter LL, Gelernter J, Anderson G, Price LH. Corticotropin releasing hormone receptor (CRHR1) polymorphisms interact with early life stress to influence the cortisol response to the Dex/CRH Test. Soc Biol Psychiatry Ann Mtg #118B, May, 2008. 257. Carpenter LL, Ross NS, Gelernter J, Anderson G, Price LH, Tyrka AR. Serotonin transporter polymorphism, fender and reported childhood maltreatment predict cortisol response to the Dex/CRH Test. Soc Biol Psychiatry Ann Mtg #280, May, 2008. 258. Schoedl AF, Costa MCP, Tyrka AR, Carpenter LL, Price LH, Mari JJ, Feijo Melo M. The clinical correlates of reported childhood sexual abuse: An association between age at trauma onset and severity of depression and PTSD in adults. International Symposium on Violence and Mental Health #71, p 51, June, 2008. 259. Hitsman B, Price LH. Neurotransmitter challenges in nicotine addiction. Eur Coll Neuropsychopharm #S.23.05, September, 2008. 260. Cui DH, Zhang HP, Kranzler HR, Blumberg HR, Tyrka A, Yang BZ, Wie F, Carpenter L, Price L, Gelenter J. Association between NGFB and affective disorder suggests potentially different genetic backgrounds between primary and drug dependence-comorbid affective disorders. Amer Soc Hum Gen Ann Mtg, November, 2008. 261. Carpenter LL, Lee JK, Tyrka AR, Anderson GM, Price LH. Elevated IL-6 response to stress in healthy adults with early life adversity. Elsevier Brain Research Meeting: Stress, Coping and Disease #P33, November, 2008. 262. Tyrka AR, Price LH, Kao H-T, Porton B, Marsella S, Carpenter LL. Reported childhood maltreatment linked to telomere length in healthy adults: A pilot study. Elsevier Brain Research Meeting: Stress, Coping and Disease #P42, November, 2008. 263. Carpenter LL, Tyrka AR, Anderson GM, Price LH. Elevated plasma IL-6 response to stress in healthy adults with early life adversity. Abstr Amer Coll Neuropsychopharm #II.55, December, 2008. 264. Tyrka AR, Price LH, Kao H-T, Porton B, Carpenter LL. Reported childhood maltreatment linked to shortened telomere length in healthy adults: A pilot study. Abstr Amer Coll Neuropsychopharm #III.172, December, 2008. 265. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Antidepressant effect of varenicline: An 8-week open- label study in depressed smokers. NCDEU Ann Mtg II.77, June, 2009. 266. Cui DH, Kranzler HR, Zhang H, Jennifer Listman, Price LH, Carpenter LL, Tyrka AR, Gelernter J. A candidate genes association study by customized low-density gene array indicates different pathways in primary affective disorders vs. comorbid with substance dependence disorders. Chinese Soc Psycho-Neuroscience Ann Mtg, October, 2009. 267. Tyrka AR, Price LH, Walters C, Anderson GM, Carpenter LL. Hypothalamic-pituitary-adrenal activity and the metabolic syndrome. Abstr Amer Coll Neuropsychopharm #II.187, December, 2009. 268. Carpenter LL, Shattuck T, Tyrka AR, Gericioti, Price LH. Effect of childhood abuse on cortisol stress response. Abstr Amer Coll Neuropsychopharm #III.60, December, 2009. 269. Tyrka AR, Price LH, Walters C, Anderson GM, Carpenter LL. Indices of the metabolic syndrome in healthy adults: Associations with hypothalamic-pituitary-adrenal axis function. Soc Biol Psychiatry Ann Mtg #516, May, 2010. 270. Carpenter LL, Shattuck TT, Tyrka AR, Geracioti TD, Price LH. Childhood physical abuse is associated with dampened cortisol stress response in adulthood. Soc Biol Psychiatry Ann Mtg #779, May, 2010. 271. Tyrka AR, Price LH, Marsit C, Carpenter LL. Methylation of leukocyte glucocorticoid receptor in healthy adults: Associations with childhood parenting experience. NY Acad Sci: Behavioral Epigenetics #41, October, 2010. 272. Tyrka AR, Price LH, Gelernter J, Walters C, Carpenter LL. BDNF Val/Met polymorphism interacts with early-life stress to predict HPA axis function. Abstr Amer Coll Neuropsychopharm #I.106, December, 2010. 273. Brown RA, Strong DR, Abrantes AM, Miller IW, Kahler CW, Niaura R, Price LH. Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. Soc Res Nicotine Tobacco Ann Mtg #PA9- 5, February, 2011. 274. Philip NS, Sweet LH, Tyrka AR, Niaura RS, Price LH, Carpenter LL. The effect of early life stress on default network activity in healthy adult subjects. Soc Biol Psychiatry Ann Mtg #261, May, 2011. 275. Tyrka AR, Price LH, Marsit C, Walters C, Wilkinson CW, Carpenter LL. Epigenetic modulation of leukocyte glucocorticoid receptor in healthy adults: Effects of childhood parenting experiences. Soc Biol Psychiatry Ann Mtg #517, May, 2011. 276. Tyrka AR, Price LH, Kao HT, Porton B, Carpenter LL. Impact of early childhood adversity on cell aging markers in adulthood. Soc Biol Psychiatry Ann Mtg #647, May, 2011. 277. Carpenter LL, Gawuga C, Tyrka AR, Price LH. CRP is associated with physical well-being, but not with early life stress or depression symptoms, in healthy adults. Abstr Amer Coll Neuropsychopharm #I.115, December, 2011. 278. Tyrka AR, Price LH, Marsit C, Walters OC, Carpenter LL. Epigenetic modulation of leukocyte glucocorticoid receptor in healthy adults: Effects of childhood parenting experiences. Abstr Amer Coll Neuropsychopharm #II.109, December, 2011.
34
Lawrence H. Price, MD
279. Tyrka AR, Price LH, Marsit C, Carpenter LL. Childhood parental loss and epigenetic modulation of the leukocyte glucocorticoid receptor in healthy adults. Soc Biol Psychiatry Ann Mtg #482, May, 2012. 280. Philip NS, Sweet LS, Tyrka AR, Price LH, Carpenter LL. Imaging biomarkers of early life stress: working memory, resting state connectivity, and the default network. Soc Biol Psychiatry Ann Mtg #545, May, 2012. 281. Dougherty DD, Carpenter LL, Bhati MT, Howland RH, O'Reardon JP, Denko T, Jacobs KJ, Pandya MM, Price LH, Tyrka AT, Evans K, Rezai AR, Baltuch G, Machado AG, Eskandar EN, Kondziolka D, Cusin C, Malone DA. A Randomized Sham-Controlled Trial of DBS of the VC/VS for Treatment-Resistant Depression. Soc Biol Psychiatry Ann Mtg #720, May, 2012.
INVITED PRESENTATIONS
1. "Use of Lithium in Bipolar Disorders and Other Psychiatric Illness," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 8/12/83. 2. "Use of Antipsychotic Drugs in Psychiatric Disorders," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 8/26/83. 3. "Alcohol and Psychotropic Drug Interactions," Connecticut Valley Hosp, Middletown, CT, 1/17/84. 4. "Lithium," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 7/13/84. 5. "Neuroleptics," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 7/18/84. 6. "Studies in Families of Depressed Patients," Dept of Psychiatry, Medical Coll of Georgia, Augusta, GA, 9/19/84. 7. "Studies in Families of Depressed Patients," Dept of Psychiatry, Dwight D Eisenhower Memorial Hosp, Fort Gordon, GA, 9/19/84. 8. "Schizophrenia: An Overview," Connecticut Valley Hosp, Middletown, CT, 10/16/84. 9. Grand Rounds: Case presentation discussant, Dept of Psychiatry, Yale-New Haven Hosp, New Haven, CT, 10/19/84. 10. "The Treatment of Affective Disorders," Connecticut Society of Hospital Pharmacists, Griffin Hosp, Derby, CT, 2/19/85. 11. "Neurobiological Research in Depression," Psychiatry 101, Dept of Psychiatry, Yale Univ, New Haven, CT, 3/25/85. 12. "Use of Antipsychotic Drugs," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 7/19/85. 13. "Use of lithium," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 7/26/85. 14. "Use of the MAOIs and Newer Antidepressants," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 8/9/85. 15. "Biological Factors in Depression and Panic," Dept of Psychiatry, Norwalk Hosp, Norwalk, CT, 1/31/86. 16. "Recent Developments in the Psychopharmacology of Depression," Family and Child Associates, Middletown, CT, 2/14/86. 17. "Receptor Sensitivity in Affective Disorders," Psychiatry 101, Dept of Psychiatry, Yale Univ, New Haven, CT, 2/24/86. 18. "Psychopharmacology of Psychosis," PGY-3 Psychopharmacology Lecture Series, Dept of Psychiatry, Yale Univ, New Haven, CT, 4/2/86. 19. "Biological Aspects of Depressive and Anxiety Disorders, "Dept of Psychiatry, Griffin Hosp, Derby, CT, 4/8/86. 20. Grand Rounds: Case presentation discussant, Dept of Psychiatry, West Haven Veterans Admin Med Center, West Haven, CT, 5/30/86. 21. "The Pharmacologic and Behavioral Treatments for Mood Disorders," Yale Alumni Weekend, Yale Univ School of Medicine, New Haven, CT, 6/7/86. 22. "Use of Antipsychotic Drugs in Psychosis," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 7/11/86. 23. "Treatment of Panic Disorder," Dept of Psychiatry, Univ of Connecticut, Farmington, CT, 8/22/86. 24. "Recent Advances in the Understanding and Treatment of Depression," Mental Health Assoc of Connecticut, Hartford, CT, 9/30/86. 25. Grand Rounds panel: "New Directions in Residency Training: What to Add, What to Subtract?" Dept of Psychiatry, Yale Univ, New Haven, CT, 11/21/86. 26. "Effects of Neuroleptics and Antidepressants on the Heart and Contraindications for Their Use," Fairfield Hills Hosp, Newtown, CT, 1/12/87. 27. "Schizophrenia," Mental Health Assoc of Connecticut (West Hartford Chapt), West Hartford, CT, 8/5/87. 28. Grand Rounds: Case presentation discussant, Yale Psychiatric Institute, New Haven, CT, 9/23/87. 29. Grand Rounds panel: "The Violent Patient," Dept of Psychiatry, Yale Univ, New Haven, CT, 3/18/88. 30. Grand Rounds: "The Treatment of Refractory Depression," Dept of Psychiatry, Waterbury Hosp, Waterbury, CT, 4/13/88.
35
Lawrence H. Price, MD
31. Grand Rounds panel: "The Biology of Depression: Clinical and Basic Studies on the Role of Serotonin," Dept of Psychiatry, Yale Univ, New Haven, CT, 4/22/88. 32. "Serotonergic effects of psychotropic drugs: Clinical studies," Biological Sciences Training Program Seminar, Dept of Psychiatry, Yale Univ, New Haven, CT, 9/12/88. 33. "Serotonergic activity in psychiatric disease," Clinical Neuroscience Lecture Series, Dept of Neurology, Yale Univ, New Haven, CT, 10/11/88. 34. "Update on depression, including biological aspects," 1988 Annual Fall Postgrad Conference, NY State Capital District Branch, Amer Psychiatr Assoc, Manchester Village, VT, 10/22/88. 35. "Psychopharmacology of depression and OCD: Newer agents,"1988 Annual Fall Postgrad Conference, NY State Capital District Branch, Amer Psychiatr Assoc, Manchester Village, VT, 10/23/88. 36. "The use of fluoxetine and other selective serotonin-reuptake inhibitors in the treatment of depression and obsessive compulsive disorder," Dept of Psychiatry, St. Joseph's Hosp, Yonkers, NY, 10/27/88. 37. Grand Rounds: Case presentation discussant, Yale Psychiatric Institute, New Haven, CT, 1/31/89. 38. Grand Rounds panel: "Depression and ecstasy: Changes in mood and behavior following alterations in serotonergic function," Dept of Psychiatry,Yale Univ, New Haven, CT, 2/24/89. 39. "Affective disorders I: Depression," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 3/5/89. 40. "New approaches in the treatment of bipolar affective disorders," Fairfield Hills Hosp, Newtown, CT, 3/20/89. 41. Grand Rounds: "The treatment of refractory depression," Institute of Living, Hartford, CT, 3/29/89. 42. "Depression: Differential diagnosis and treatment for the primary physician," Sandoz Teleconference Series, New Haven, CT, 3/31/89. 43. Grand Rounds: Case presentation discussant, Dept of Psychiatry, Yale Univ, New Haven, CT, 4/14/89. 44. Grand Rounds: "Serotonergic function in the neurobiology and psychopharmacology of depression," Dept of Psychiatry, Univ of Rochester, Rochester, NY, 4/19/89. 45. Grand Rounds: "The treatment of refractory depression," Dept of Psychiatry, Hosp of St. Raphael, New Haven, CT, 5/18/89. 46. "Serotonin and its effects on human behavior: A role for serotonin in the mechanism(s) of action of antidepressant drugs--Clinical data," Dista Products Co. (Eli Lilly and Co.), Atlanta, GA, 10/7/89. 47. "Affective disorders I and II," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 10/19/89. 48. Grand Rounds panel (moderator): "Psychotherapies and obsessive compulsive disorder," Dept of Psychiatry,Yale Univ, New Haven, CT, 10/20/89. 49. Grand Rounds: "Diagnosis and treatment of depression in primary care," Dept of Medicine, Univ of Connecticut, Farmington, CT, 11/15/89. 50. Grand Rounds: "Treatment of refractory depression," Stony Lodge Hosp, Briarcliff Manor, NY, 1/18/90. 51. "Affective disorders I and II," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 2/1/90. 52. "Serotonin and depression: Implications for pathophysiology and treatment," Institute of Living, Hartford, CT, 2/8/90. 53. Grand Rounds: "Serotonin and depression: Implications for pathophysiology and treatment," Dept. of Psychiatry, Jefferson Med College, Thomas Jefferson Univ, Philadelphia, PA, 5/2/90. 54. Paper session (co-chair): "Treatment issues in anxiety disorders," Ann Mtg, Amer Psychiatr Assoc, NY, NY, 5/16/90. 55. "Pharmacological strategies for refractory depression," Greater Bridgeport Mental Health Center, Bridgeport, CT,5/17/90. 56. Grand Rounds: "New strategies in the treatment of refractory depression," Elmcrest Psychiatric Institute, Portland, CT, 5/23/90. 57. "Treatment of refractory depression," Dept. of Psychiatry, United Hosp, Portchester, NY, 6/7/90. 58. "The neurobiology and treatment of refractory depression: Serotonergic perspectives," Research Scientist Developmt Awardees Conference, Natl Inst Ment Hlth, Chevy Chase, MD, 6/14/90. 59. "Update on depression for the primary care physician," Manchester Memorial Hosp, Manchester, CT, 9/11/90. 60. "Affective disorders I and II," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 9/13/90. 61. "General strategies for managing an inadequate response to an adequate treatment trial," Planning Mtg on Treatmt- Resistant Depression, Natl Inst Ment Hlth, Rockville, MD, 9/26/90. 62. "Obsessive compulsive disorder: Board review lecture," Videotaped Review of American Psychiatry, Specialty Preparation, Inc, Pelham, NY, 11/30/90.
36
Lawrence H. Price, MD
63. Grand Rounds: Case presentation discussant--Rapid-cycling bipolar disorder, Dept of Psychiatry,Yale Univ, New Haven, CT, 1/11/91. 64. "Affective disorders I and II," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 1/31/91. 65. Grand Rounds: Case presentation discussant--Treatment-resistant obsessive compulsive disorder, Dept of Psychiatry,Yale Univ, New Haven, CT, 1/14/91. 66. "The neurobiology of depression: Serotonin and antidepressant treatments," 25th Anniv Sympos, Connecticut Mntl Hlth Cntr, Dept of Psychiatry,Yale Univ, New Haven, CT, 9/21/91. 67. Medical Grand Rounds: "Diagnosis and treatment of depression in the primary care setting," Robert Packer Hosp, Sayre, PA, 9/27/91. 68. "OCD rating workshop: The Y-BOCS," Investigators Meeting, Sertraline vs. Clomipramine vs. Placebo Study, Pfizer Pharmaceuticals, NY, NY, 9/30/91. 69. "Affective disorders," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 10/7/91. 70. Grand Rounds: "Obsessive compulsive disorder in a 75-year-old woman," Dept of Psychiatry, NY Hosp-Cornell Med Center, Westchester Division, White Plains, NY, 10/11/991. 71. "Serotonergic function in depression," Brentwood VAMC, Dept of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, 10/16/91. 72. Symposium (co-chair): "Neurobiology of affective disorders," 3rd Ann Bristol-Myers Squibb Sympos on Neuroscience Research, Dept of Psychiatry, Yale Univ, New Haven, CT, 10/25/91. 73. Grand Rounds: Case presentation discussant--"Short-term treatment of severe adult psychopathology," Yale Psychiatric Institute, New Haven, CT, 10/29/91. 74. "Recent developments in the treatment of refractory depression," Greater Bridgeport Mental Health Center, Bridgeport, CT, 12/17/91. 75. "Affective disorders," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 1/27/92. 76. "The role of serotonin uptake inhibitors," in "Refractory depression--Treatment strategies in clinical practice: An international symposium," Communications Media for Education, Inc, Toronto, Canada, 2/15/92. 77. Grand Rounds: "Recent studies in the clinical neurobiology of cocaine," Dept of Psychiatry, Albert Einstein Coll of Medicine, NY, NY, 3/20/92. 78. Workshop: "Psychopharmacology for psolicitors," Connecticut Legal Rights Project, Middletown, CT, 4/7/92. 79. "Affective disorders," Comprehensive Review of Psychiatry Course (Part I), Dept of Psychiatry, Yale Univ, New Haven, CT, 9/14/92. 80. Grand Rounds: "Serotonin and psychiatric disorders," Dept of Psychiatry, Danbury Hosp, Danbury, CT, 10/14/92. 81. Grand Rounds: "Serotonin and neuropsychiatric disorders," Dept of Psychiatry, St. Vincent's Hospital (Westchester Facility), Harrison , NY, 1/13/93. 82. "Fluvoxamine for depression," in "Genetic and treatment factors in nonpsychotic psychiatric disorders," Sanibel Island Symposium, Fort Myers, FLA, 2/12/93. 83. "Depression and mania," in "The Neuroscience Revolution: Promises for the future of psychiatry," Connecticut Mntl Hlth Cntr, New Haven, CT, 2/25/93. 84. Grand Rounds: "The psychopharmacology of affective disorders," Silver Hills Hosp, New Canaan, CT, 3/3/93. 85. "The treatment of refractory depression: An update," Rye Hosp Center, Rye, NY, 3/22/93. 86. "Recent advances in the treatment of bipolar and major depressive disorders in children and adults," National Alliance for the Mentally Ill-Children & Adolescents Network, Woodbridge, CT, 3/24/93. 87. "Bipolar and major depressive disorders in adolescents and adults: Neurobiology, neuropharmacology, and current treatments," in "Recent findings from the neuroscience revolution," Yale Univ Schl of Med Office of Postgrad and Cont Med Educ, The Brain Center, New Seabury, MA, 7/30-31/93. 88. Grand Rounds: "Overview of depression research in the Dept of Psychiatry-- Introduction," Dept of Psychiatry, Yale Univ, New Haven, CT, 10/22/93. 89. Grand Rounds panel (moderator): "Childhood psychiatric disorders grown up: Implications for practice and training," Dept of Psychiatry, Yale Univ, New Haven, CT, 2/18/94. 90. "New advances in psychopharmacology: Fluvoxamine," in "Second Ann Educational Program," Am Soc Clin Psychopharmacology, Philadelphia, PA, 5/22/94. 91. Presenter, "Psychotherapy of depression," Continuous Clinical Case Conference, Amer Psychiatr Assoc Ann Mtg, Philadelphia, PA, 5/23/94.
37
Lawrence H. Price, MD
92. Grand Rounds: "Neuropsychiatric complications of neural transplants," Dept of Neurology, Univ of Chicago, Chicago, IL, 8/10/94. 93. "Depression and receptor site physiology," Bristol-Myers Squibb Mood Preceptorship, Dept of Psychiatry, Hosp of St Raphael, New Haven, CT, 9/20,23/94. 94. "Depression and receptor function," in "Electroconvulsive therapy and treatment of the resistant patient," Dept of Psychiatry, Hosp of St Raphael, New Haven, CT, 10/5/94. 95. Grand Rounds: "Serotonin in neuropsychiatry--Recent findings using tryptophan depletion," Dept of Psychiatry, Coll of Physicians and Surgeons, Columbia Univ, NY, NY, 10/7/94. 96. “Augmentation strategies in depression,” in “Mental health--An ecological perspective: Connecticut-based research on etiology and treatment issues,” Mental Health Assoc of CT, Meriden, CT, 11/2/94. 97. “The diagnosis and treatment of depression for primary care providers,” Hill Health Center, New Haven, CT, 11/10/94. 98. "Drugs, sex, and AIDS," The Putney School, Putney, VT, Nov 20, 1994. 99. "Antimanic treatments," in "Psychopharmacology course for advanced nurses, psychiatric residents, and psychiatrists," State of CT Dept of Mental Health, New Haven, CT, 3/6/95. 100. "Common psychiatric problems in primary care: A clinical case discussion," Hill Health Center, New Haven, CT, 3/16/95. 101. Grand Rounds: "Recent advances in the diagnosis and treatment of obsessive compulsive disorder, " Dept of Psychiatry, Bristol Hosp, Bristol, CT, 3/21/95. 102. Grand Rounds: "Recent advances in the diagnosis and treatment of obsessive compulsive disorder, " Dept of Psychiatry, Danbury Hosp, Danbury, CT, 3/22/95. 103. "Neurobiology and pharmacotherapy of depression, " in "New knowledge of mood disorders: Promises for the future," Conn Mntl Hlth Cntr, New Haven, CT, 3/28/95. 104. "Current approaches to the treatment of patients with refractory depression," Alabama Psychiatr Soc Ann Mtg, Point Clear, AL, 4/7/95. 105. "Tryptophan depletion in neuropsychiatric disorders," in "Clinical pharmacology of antidepressant drugs," Dept of Psychiatry, New York Univ, NY, NY, 4/22/95. 106. Grand Rounds: "The obsessive compulsive disorder spectrum," Dept of Psychiatry, New York Univ, NY, NY, 5/4/95. 107. "Update on obsessive compulsive disorder," Solvay Pharmaceuticals (spons), Waterbury, CT, 5/10/95. 108. Grand Rounds: "OCD spectrum disorders and treatment options," Dept of Psychiatry, St Elizabeth's Hosp, Boston, MA, 5/15/95. 109. "Serotonergic function in neuropsychiatric disorders: Recent findings using tryptophan depletion," in "Psychopharmacology Winter Conference Series," Dept of Psychiatry, Mass Genl Hosp, Harvard Medical School, Boston, MA, 6/9/95. 110. "Obsessive compulsive disorder update," Dept of Psychiatry, Catholic Medical Center, New Bedford, NH, 6/14/95. 111. Grand Rounds: "Obsessive compulsive disorder update," Hall-Brooke Hosp, Westport, CT, 9/6/95. 112. Grand Rounds: "Update on obsessive compulsive disorder," Dept of Psychiatry, Stamford Hosp, Stamford, CT, 9/14/95. 113. Grand Rounds: "Refractory depression in a 68-year-old man," Dept of Psychiatry, New York Hosp-Cornell Med Center, Westchester Div, White Plains, NY, 9/19/95. 114. Grand Rounds: "The newer antidepressants -- Similarities and differences," Dept of Psychiatry, Univ of Mass Med Schl, Worcester, MA, 10/19/95. 115. Rapporteur, "Pharmacological challenges: Implications for treatment," in "Treatment-refractory obsessive compulsive disorder," Natl Inst Ment Hlth and Obsess Comp Foundtn, Durham, NH, 10/23-25/95. 116. "Depression," Dept of Neurology, Yale Univ Schl of Med, New Haven, CT, 10/26/95. 117. "Impulse control and disorders related to OCD," in "Advances in psychiatry VII, 1995: Schizophrenia, OCD and depression," Dept of Postgrad Med, Univ of Mich Med Schl, Ann Arbor, MI, 11/3/95. 118. "Depression," in "Clinical psychopharmacology update program," Conn Mntl Hlth Cntr, New Haven, CT, 11/28/95. 119. Grand Rounds: "Treatment of refractory depression," Dept of Psychiatry, Northport VAMC, Northport, NY, 1/10/95. 120. "Antidepressant augmentation strategies," in "Psychopharmacology Lecture Series," Mass Mntl Hlth Cntr, Dept of Psychiatry, Harvard Medical School, Boston, MA, 1/19/95. 121. Medical Grand Rounds: "Obsessive compulsive disorder and spectrum conditions: Recent developments, " Dept. of Medicine, New Britain Gen Hosp, New Britain, CT, 2/8/96. 122. "New treatment modalities in obsessive compulsive disorder," Mid-Winter Mtg, Maine Osteopathic Assoc, Portland, ME, 2/16/96.
38
Lawrence H. Price, MD
123. "The use of fluvoxamine and other strategies in the treatment of obsessive compulsive disorder," Dept of Psychiatry, St Vincent's Med Cntr, Bridgeport, CT, 3/26/96. 124. Grand Rounds: "Update on the diagnosis and treatment of obsessive compulsive disorder," Dept of Psychiatry, Danbury Hosp, Danbury, CT, 4/3/96. 125. "Advances in obsessive compulsive disorder," Solvay Pharmaceuticals (spons), Newton, MA, 4/11/96. 126. "Update on the diagnosis and treatment of panic and social phobia," SmithKline Beecham Pharmaceuticals (spons), Washington, CT, 4/14/96. 127. "New indications for paroxetine: panic disorder [videotape]," SmithKline Beecham Pharmaceuticals (spons), New Haven, CT, 5/10/96. 128. Grand Rounds: "What to do with the treatment-resistant depressed patient," Dept of Psychiatry, Hosp of St Raphael, New Haven, CT, 5/16/96. 129. "Augmentation strategies for treatment-resistant OCD," Psychiatric Physicians, P.C., Danvers, MA, 5/16/96. 130. "Recent advances in the diagnosis and treatment of OCD," Dept of Psychiatry, Berkshire Health Systems, Pittsfield, MA, 6/5/96 131. Grand Rounds: "Obsessive compulsive spectrum disorders," Dept of Psychiatry, Ellis Hosp, Schenectady, NY, 6/11/96. 132. "The neurobiology of cocaine (and other stimulants) and phencyclidine: Board review lecture," Videotaped Review of American Psychiatry, Specialty Preparation, Inc, Pelham, NY, 7/28/96. 133. "The neurobiology of opioids and cannabis (with a few words on nicotine and caffeine): Board review lecture," Videotaped Review of American Psychiatry, Specialty Preparation, Inc, Pelham, NY, 7/28/96. 134. "Patient interviews for the Board examination," Videotaped Review of American Psychiatry, Specialty Preparation, Inc, Pelham, NY, 9/20/96. 135. Grand Rounds: Case presentation discussant, Dept of Psychiatry, Providence VAMC, Providence, RI, 10/23/96. 136. Psychopharmacology Lecture Series: "Management of treatment resistant depression," Dept of Postgrad and Contin Educ, McLean Hosp, Belmont, MA, 10/31/96. 137. "Serotonin in psychiatry: Clinical studies with tryptophan infusion and depletion," in "First Annual Research Symposium on Mental Health Sciences," Dept of Psychiatry and Human Behavior, Brown Univ Schl of Med, Providence, RI, 11/7/96. 138. "Current approaches to refractory depression," in "George R. Heninger --30 Years at Yale: A Generation of Progress," Dept of Psychiatry, Yale Univ Schl of Med, New Haven, CT, 1/10/97. 139. "The differential diagnosis of mood disorders," RI Employee Assistance Program, Inc, Warwick, RI, 3/14/97. 140. Grand Rounds: "Recent advances in the diagnosis and treatment of obsessive compulsive disorder, " Charter Brookside Hosp, Nashua, NH, 3/18/97. 141. "The treatment of refractory depression: Focus on combination strategies," Butler Hosp Staff Assoc, Butler Hosp, RI, 4/10/97. 142. Grand Rounds: "Recent developments in obsessive compulsive disorder," Dept of Psychiatry, Hosp of St Raphael, New Haven, CT, 6/19/97. 143. "Recent developments in the use of SSRIs in mood, anxiety, and other disorders," Solvay Pharmaceuticals (spons), Cranston, RI, 6/25/97. 144. Grand Rounds: "Evolving approaches to the treatment of refractory depression," Dept of Psychiatry, St Luke's Hosp, New Bedford, MA, 10/7/97. 145. Clinical Case Conference Series (discussant): "Refractory depression in a 40-yr-old male with Axis II Features," Butler Hosp, Providence, RI, 10/23/97. 146. Grand Rounds: "Current approaches to refractory depression," Dept of Psychiatry, Brockton VAMC, Brockton, MA, 10/30/97. 147. "Serzone: Take a second look" (discussant), Bristol-Myers-Squibb (spons), Providence, RI, 11/5/97. 148. "Update on bipolar disorder: Diagnosis and treatment," Abbott Laboratories (spons), Providence, RI, 11/13/97. 149. Grand Rounds: "Obsessive compulsive and spectrum disorders," Portsmouth Hosp, Portsmouth, NH, 12/16/97. 150. Advisor, 1998 Janssen CNS Summit, "Cognition: From research to rehabilitation," Rancho Mirage, CA, 1/26-29/98. 151. "Update on bipolar disorder: Diagnosis and treatment," Behavioral Health Specialists, Warwick, RI, 2/17/98. 152. Invited attendee, Pfizer International Psychiatry Conference, "Zoloft -- A decade of discovery," Berlin, Germany, 3/20-23/98. 153. Program moderator, "Living with mood disorders," Butler Hosp, Providence, RI, 5/21/98. 154. Program moderator, "Second Annual Behavioral Health Speaker Series and Family Day: Focus on Women's Health Issues and Pharmacoeconomics," Butler Hosp and Eli Lilly & Co (spons), Newport, RI, 6/13/98.
39
Lawrence H. Price, MD
155. "Recent studies in 5-HT and HPA axis function in depressed and healthy humans," CNS Diseases Research Dept., Experimental Station, Dupont Merck, Wilmington, DE, 6/16/98. 156. "Mirtazapine: Pharmacological and clinical profile," Dept of Psychiatry, Landmark Woonsocket Hosp, Woonsocket, RI, 8/11/98. 157. "The clinical use of citalopram [videotape]," Forest Laboratories (spons), Providence, RI, 8/12/98. 158. "OCD spectrum disorders: The use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression and other non-obsessional conditions," Professional Lecture Programs in Psychiatry, Butler Hosp, Providence, RI, 9/19/98 159. "Update on OCD spectrum disorders: Diagnosis and treatment," Holyoke Hosp and Solvay Pharmaceuticals (spons), Springfield, MA, 10/1/98. 160. Grand Rounds: "Recent advances in the diagnosis and treatment of obsessive compulsive disorder and obsessive compulsive spectrum disorders," Center for Behavioral Health, Holyoke Hosp, Holyoke, MA, 10/2/98. 161. "Bipolar disorder: What's up with that?," Abbott Laboratories (spons), Hyannis, MA, 10/17/98. 162. Advisor, Second Annual Janssen CNS Summit, "Psychiatric genetics and psychopharmacology," Tempe, AR, 2/8- 11/99. 163. "Research activities in the Butler Hospital Mood Disorders Program: Studies on the drug treatment of mood disorders," Board of Trustees, Butler Hosp, Providence, RI, 3/23/99. 164. "Advances in psychopharmacology," 1999 Primary Care Update, RI Acad of Fam Phys and Dept of Fam Med, Memorial Hosp of RI, Brown Univ Schl Med, Providence, RI, 5/15/99. 165. "Prevention of relapse in depression: Integrated treatment approaches -- Pharmacotherapy," Blue Cross/Blue Shield of RI and National Alliance for the Mentally Ill of RI, Warwick, RI, 6/11/99. 166. "An update on the assessment and treatment of obsessions and compulsions," Solvay Pharmaceuticals (spons), Boston, MA, 9/23/99. 167. Grand Rounds: "Bipolar disorder: Recent developments in diagnosis and treatment," Champlain Valley Physicians Hosp Med Cntr, Plattsburgh, NY, 9/24/99. 168. Program moderator, "Treatment and genetics of bipolar disorder in the new millennium," Butler Hosp and Glaxo- Wellcome (spons), Providence, RI, 9/29/99. 169. "Long-term treatment of depression: What to do when your antidepressant stops working" (discussant), Bristol- Myers-Squibb (spons), Providence, RI, 10/29/99. 170. "Augmentation strategies for treatment-resistant depression," in "Academic Conference Series," Dept of Postgrad and Contin Educ, McLean Hosp, Belmont, MA, 1/28/00. 171. "New advances in choosing an antidepressant," Wyeth-Ayerst (spons), Gainesville, FL, 3/8/00. 172. Grand Rounds: "Refractory depression: Advances in biomedical approaches," Dept of Psychiatry, Univ of Fla, Gainesville, FL, 3/9/00. 173. "Psychopharmacologic treatment of bipolar disorders with lithium and anticonvulsants," in "Advanced psychopharmacology," RI State Nurses Assoc, Providence, RI, 3/25/00. 174. "Update on the psychopharmacology of OCD," in "Advances in the treatment of anxiety disorders," Office of Contin Prof Educ, Univ of South Fla Coll Med, Tampa, FL, 6/10/00. 175. "OCD spectrum disorders," Solvay Pharmaceuticals (spons), Albany, NY, 6/23/00. 176. "Differential diagnosis of depression and anxiety," in "Current management decisions in depression and anxiety," Health Science Cntr for Contin Med Educ and World Medical Leaders.com, NY, NY, 6/26/00. 177. "Mental Health Clinical Update: Primary care recognition and treatment of obsessive-compulsive spectrum disorders" Baptist Health System of South Fla, Miami, FL, 9/13/00. 178. Grand Rounds: "Recent developments in the treatment of refractory depression," Dept of Psychiatry, St Luke's Hosp, New Bedford, MA, 10/3/00. 179. "Pathophysiology of treatment-resistant depression," in "Novel approaches to the patient with treatment-resistant depression," Postgrad Institute for Medicine, Providence, RI, 10/14/00. 180. "Novel approaches to the treatment of refractory depression," Rhode Island Psychiatric Society, Providence, RI, 12/4/00. 181. "Recent advances in the treatment of depression," in "Mental illness: A global burden," Butler Hosp, Providence, RI, 4/3/01. 182. "Vagal nerve stimulation (VNS): A new treatment for depression?," Board of Trustees, Butler Hosp, Providence, RI, 4/24/01. 183. "Bipolar disorder: Recent issues in diagnosis and treatment," in "Science Lecture Series," Dept of Psychiatry, Tufts Univ, New Engl Med Cntr, Boston, MA, 5/14/01. 184. "Remission as a treatment goal in psychiatry," Northern RI Mental Health Center, Woonsocket, RI, 6/14/01.
40
Lawrence H. Price, MD
185. "Long-term treatment of bipolar disorder," in "Long-term treatment options: Improving outcomes in depression," Postgrad Institute for Medicine, Ft Lauderdale, FL, 10/26/01. 186. "Advances in the diagnosis and treatment of bipolar disorder," in Mental Health Colloquium Series, Mntl Hlth Behav Sci Service, Providence VAMC, Providence, RI, 11/28/01. 187. "Recent developments in the diagnosis and treatment of bipolar disorder: A critical overview," Rhode Island Psychiatric Society, Cranston, RI, 2/24/03. 188. "Remission as a goal of psychopharmacological treatment," American Psychiatric Nurses Association, Cambridge, MA, 6/19/03. 189. "Bipolar disorder: A critical overview of current trends," Dept. of Psychiatry, Backus Hosp., Norwich, CT, 7/24/03 190. "Evaluating maintenance strategies for the long-term management of bipolar disorder," Gateway Healthcare, Pawtucket, RI, 8/13/03. 191. "Evaluating maintenance strategies for the long-term management of bipolar disorder," Southeastern Mental Health Authority, Norwich, CT, 9/9/03. 192. "Bipolar disorder: Recent developments in pharmacologic treatment," GlaxoSmithKline (spons), Wellesley, MA, 11/05/03. 193. "The long-term management of bipolar I disorder," GlaxoSmithKline (spons), Providence, RI, 12/02/03. 194. "Clinical use of atypical neuroleptics: Case discussions," AstraZeneca (spons), Providence, RI, 2/24/04. 195. "Antidepressants and suicidality," Rhode Island College, Providence, RI, 5/6/04. 196. "Challenges in the treatment of bipolar I disorder," Pfizer (spons), Worcester, MA, 1/13/05. 197. Clinical Case Conference Series (discussant): "Homicidal and suicidal obsessions in a 27-year-old male with psychotic illness," Butler Hosp, Providence, RI, 1/27/05. 198. "Clinical use of atypical neuroleptics: Emerging findings," Pfizer (spons), Providence, RI, 3/17/05. 199. Course director, "6th Annual Genetics and Public Health Conference – Genetics and mental health: Research and reality," State of Rhode Island and Brown Med School, Warwick, RI, 4/28/05. 200. "Atypical neuroleptics in the treatment of bipolar disorder," Riverwood Mental Health Services, Warren, RI, 5/12/05. 201. "Improving outcomes in patients with bipolar disorder," Center for Medical Knowledge, Providence, RI, 6/1/05. 202. "Long-term management strategies for bipolar I disorder," GlaxoSmithKline (spons), Providence, RI, 9/29/05. 203. "Ziprasidone in the treatment of bipolar disorder," Pfizer (spons), Providence, RI, 10/25/05. 204. “Managing the medical and psychiatric health of the patient with bipolar disorder,” CME LLC, Chicago, IL, 11/19/05. 205. “Managing the medical and psychiatric health of the patient with bipolar disorder,” CME LLC, Philadelphia, PA, 12/3/05. 206. Clinical Case Conference Series (discussant): "An empty house," Butler Hosp, Providence, RI, 2/23/06. 207. “Alternative treatments for depression: Fact and fiction,” Prof Lect Progr in Psychiatry, Butler Hosp, Providence, RI, 2/28/06. 208. “From human lab to clinical trial: Mood and anxiety disorders,” in “Workshop on perspectives on translational research,” Dept of Psychiatry and Human Behavior, Brown Med Schl, Providence, RI, 3/9/06. 209. “Treatment of bipolar mania and schizophrenia,” AstraZeneca (spons), Providence, RI, 3/28/06. 210. “Tolerability of quetiapine,” AstraZeneca (spons), Providence, RI, 9/13/06. 211. Grand Rounds: "Pharmacological approaches to the treatment of refractory depression," Dept. of Psychiatry, Oregon Health and Sciences Univ, Portland, OR, 10/24/06. 212. “Tolerability of quetiapine,” AstraZeneca (spons), Providence, RI, 11/13/06. 213. Clinical Case Conference Series (discussant): "Depression refractory to treatment as a result of decreased cognitive functioning from a head injury," Butler Hosp, Providence, RI, 10/31/07. 214. "Childhood maltreatment and adult psychopathology: Pathways to HPA axis dysfunction," opening address in "An International Symposium on Violence and Mental Health," Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 6/20/08. 215. Clinical Case Conference Series (discussant): "The emerging diagnosis: A 20-year-old man troubled by images of horror," Butler Hosp, Providence, RI, 5/27/09. 216. "Neurobiology of mood disorders: A review and update, I and II," MD Conferences/Psychiatry Review Course, MV Celebrity Equinox, 10/11/09. 217. "Adult neurobiological sequelae of early life stress: Focus on HPA axis dysfunction, I and II," MD Conferences/Psychiatry Review Course, MV Celebrity Equinox, 10/15/09. 218. "Treatment-resistant depression: The evolving role of neuromodulation strategies," MD Conferences/Psychiatry Review Course, MV Celebrity Equinox, 10/20/09. 219. "Emerging treatment options for depression, 2010," in Mental Health Colloquium Series, Mntl Hlth Behav Sci Service, Providence VAMC, Providence, RI, 1/20/10.
41
Lawrence H. Price, MD
220. Clinical Case Conference Series (discussant): "A 65-year-old woman with chronic and suicidality," Butler Hosp, Providence, RI, 5/26/10. 221. Clinical Case Conference Series (discussant): "Treatment-resistant depression in a medically complex patient," Butler Hosp, Providence, RI, 2/23/11. 222. Grand Rounds: "Tardive dyskinesia: Recent findings and current status," Dept. of Neurology, Brown Alpert Medical School, Providence, RI, 7/20/11. 223. “A clinical perspective on suicide: How data can and cannot inform clinical practice,” in “Combined Trainee Suicide Workshop,” Dept of Psychiatry and Human Behavior, Brown Alpert Medical School, Providence, RI, 10/25/11. 224. Grand Rounds: "Tardive dyskinesia: Recent findings and current status," in "Tardive dyskinesia: An Interdisciplinary Perspective," Dept of Psychiatry and Human Behavior, Brown Alpert Medical School, Providence, RI, 2/1/12. 225. "Are we over-prescribing?" (panelist), Faculty Workshop, Dept of Psychiatry and Human Behavior, Brown Alpert Medical School, Providence, RI, 4/20/12.
GRANTS
1. University of Michigan Student Medical Research Grant, "Computer simulation of motivation and action," Princ. Investig.; 6/75-8/75, $900. 2. NIMH P50 MH30929, "Clinical Science Research Center in Psychiatry," Co-investig.; 9/77-8/97, $3,425,686 [most recent funding cycle]. 3. NIMH P01 MH25642, "Neurobiologic basis of major psychiatric disorders," Co-investig.;7/78-6/96, $3,458,203 [most recent funding cycle]. 4. NIMH R01 MH36229, "Monoamine receptor sensitivity and antidepressant drugs," Co-investig.; 4/82-8/92, $357,469 [most recent funding cycle]. 5. NIDA P05 DA04060, "Clinical Research Center for Opioid and Cocaine Use" (Component: "Clinical neurobiology of cocaine withdrawal and administration"), Component Princ. Investig.; 8/86-7/96, $619,142 [most recent funding cycle]. 6. CIBA-GEIGY Pharmaceuticals, "Anafranil vs. placebo in the treatment of OCD - Extension Phase," Princ. Investig.; 6/87-1/89, $36,500. 7. NIMH K08 MH00579 (Clinical Investigator Award), "Neurobiology and treatment of refractory depression," Princ. Investig.; 8/87-7/90, $160,474. 8. Pfizer Pharmaceuticals, "Double-blind comparison of SM-3997 and placebo in outpatients with depression," Princ. Investig.; 5/88-6/90, $60,600. 9. NIDA R18 DA06190, "Treatment Research Unit: Reducing AIDS risk by pharmaco- and psychotherapy," Co- investig.; 8/89-9/94, $2,685,673. 10. NIMH R01 MH47894, "Rapid treatment of major depression, " Co-investig.; 5/92-4/95, $461,143. 11. Parke-Davis, "A single-blind, placebo-controlled crossover study of oral CI-988 for anxiety in patients with GAD," Princ. Investig.; 5/92-6/93, $36,980. 12. Miles Pharmaceuticals, "A multicenter, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of three fixed doses of ipsapirone CR (Bay Q7821) vs placebo in outpatients with moderate to severe major depressive disorder (MDD)," Princ. Investig.; 8/93-8/94, $124,800. 13. Stanley Foundation Research Awards Program, National Alliance for the Mentally Ill, "The role of monoaminergic function in the mechanism of action of lithium in mania," Princ. Investig.; 8/94-8/96, $128,000. 14. NIDA R01 DA09330-01, "Serotonin/dopamine antagonism of cocaine effect," Princ. Investig.; 9/94-8/97, $673,686; extended to 8/98, with administrative increase of $55,532. 15. Solvay Pharmaceuticals, Unrestricted grant, Princ. Investig.; 5/95, $50,000. 16. Departmental Research Award, Brown Univ. Dept. of Psychiatry and Human Behavior, "The genetics of dopamine b- hydroxylase in psychotic and nonpsychotic depression," Princ. Investig.; 7/97 - 6/98, $15,888. 17. Solvay Pharmaceuticals, "A multicenter, double-blind, placebo-controlled, parallel group study of the safety, tolerability and efficacy of three fixed doses of fluvoxamine vs placebo in outpatients with major depressive disorder," Princ. Investig.; 9/97 - 8/98, $242,120. 18. Pfizer, Inc., "A phase III, randomized, placebo-controlled study evaluating the safey and outcome of treatment with oral ziprasidone in subjects with mania receiving lithium," Princ. Investig.; 1/98 - 1/99, $169,313. 19. Pfizer, Inc., "An open extension study evaluating the safety and outcome of 40-160 mg daily of oral ziprasidone in the treatment of subjects who have participated in Protocol 602," Princ. Investig.; 1/98 - 1/00, $36,300.
42
Lawrence H. Price, MD
20. Forest Laboratories, Inc., "An open-label evaluation of the efficacy, safety, and dosing of citalopram in outpatients with depression," Princ. Investig.; 2/98 - 3/99, $40,040. 21. Forest Laboratories, Inc.,"An open-label extension of citalopram treatment in outpatients with depression," Princ. Investig; 3/98- 3/99, $29,912. 22. Eli Lilly and Co., "Comparative efficacy of switching SSRI nonresponders to fluoxetine vs continued antidepressant treatment with the same SSRI," Princ. Investig.; 3/98 - 3/00, $74,961. 23. Pfizer, Inc., "Validation of serial CSF collection method for assessment of central serotonergic function," Princ. Investig.; 7/98 - 10/98, $47,956. 24. Merck Research Laboratories, "A double-blind, multicenter study of two doses of L-759274 vs paroxetine hydrochloride and placebo in the treatment of outpatients with major depressive disorder," Investigator; 8/99 - 3/00, $197,520. 25. Pfizer, Inc., "A six-week, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of 3 doses of CP-448,187 (0.5, 3, and 10 mg) and fluoxetine (Prozac) in subjects with major depressive disorder," Princ. Investig.; 5/00- 5/02, $82,797. 26. NIMH RO1 MH58866-01, "Combined treatment for depressed inpatients," Co-Princ. Investig.; 6/00 – 7/05, $2,352,122. 27. NCI R21 CA88297-01, "Behavioral vulnerability to early smoking relapse," Co-Investig.; 7/00 – 6/02, $362,500. 28. Cyberonics, "A multicenter, pivotal, safety and efficacy study of the NeuroCybernetic Prosthesis (NCP) system in patients with depression," Co-Investig., 2/00-2/02, $117,145. 29. Cyberonics, "A long-term, prospective, multicenter study to compare the clinical, quality of life, and health care utilization outcomes of the NeuroCyberonic Prosthesis (NCP) System to the standard of care treatment in patients with depression," Co-Investig., 1/01-1/03, $61,680. 30. Cyberonics, "CSF neurochemical correlates of vagus nerve stimulation in depressed patients," Co-Investig., 1/01-1/03, $108,725. 31. Thuris Corp., "Evoked response potentials in mood disorders. I.," Princ. Investig.; 6/01-6/02, $10,000. 32. Scirex Corp./Corcept Therapeutics, Inc., "1073-02: A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of C-1073 (mifepristone) in patients with major depressive disorder with psychotic features," Co-Investig., 11/01-11/02, $14,967. 33. Scirex Corp./Corcept Therapeutics, Inc., "1073-02: A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of C-1073 (mifepristone) in patients with major depressive disorder with psychotic features who are not receiving antidepressants or antipsychotics," Co-Investig., 11/01-11/02, $14,967 34. Merck Research Laboratories, "A worldwide, multicenter, double-blind, parallel, active-controlled, long-term safety study of MK-0869 in outpatients with major depressive disorder (Protocol 066-00)," Princ. Investig.; 2/02-2/03, $251,880. 35. Cephalon, Inc. "An open-label, 8-week study with flexible doses of Gabitril™ (tiagabine hydrochloride) in patients with major depressive disorder with anxiety (MDD-A)," Co-Investig., 3/02-3/03, $127,500. 36. Thuris Corp., "Evoked response potentials in mood disorders. II.," Princ. Investig.; 7/02-8/03, $45,555. 37. American Cancer Society RSGPB PBP-103382, "Improving smoking cessation in smokers with depressive symptoms," Co-Investig., 7/02-6/06, $1,264,374. 38. Medtronic, Inc., "Electrical Stimulation of the Anterior Limb of the Internal Capsule to Treat Major Depressive Disorder," Co-Investig., 10/02-9/04, $315,000. 39. Pfizer, Inc., "Sertraline treatment and cortisol response to the DEX/CRH test in healthy subjects," Co-Investig., 12/03- 12/06, $125,260. 40. NIMH RO1 MH068767-01, "DEX/CRH response: Mood/anxiety disorder endophenotype?," Co-Investig.; 4/04–3/08, $1,227,776. 41. NCCAM/NIMH RO1 AT001742-01, "Double-blind, placebo-controlled study of SAMe vs. escitalopram in MDD," Princ. Investig.; 4/04-3/09, $1,087,938. 42. US Dept of Defense, "Perceived early life stress and DEX/CRH test response as predictors of psychological sequelae following exposure of healthy adults to war stress," Co-Investig.; 7/04–6/05, $40,000. 43. UCB Pharma, Inc., "Keppra treatment and cortisol response to the DEX/CRH test in healthy subjects," Co-Investig.; 6/04–12/06, $111,624. 44. Sepracor, Inc. ESRC101, "Eszopiclone treatment and cortisol response to HPA Axis tests," Co-Investig; 9/06–6/08, $254,319. 45. Cyberonics, Inc., “Randomized comparison of outcomes in patients with treatment-resistant depression who receive VNS therapy administered at different amounts of electrical charge,” Co-Investig., 11/07-9/10; $286,350.
43
Lawrence H. Price, MD
46. NIDA RO1 DA023190-01A1, "Sequential use of fluoxetine for smokers with elevated depressive symptoms," Co- Investig.; 9/07–3/12, $2,374,108. 47. Medtronic, Inc., “RECLAIM deep brain stimulation (DBS) clinical study for treatment-resistant depression,” Co- Investig., 4/09-6/11. 48. Neuronetics, Inc., “NeuroStar Transcranial Magnetic Stimulation Therapy® System: Data management, analysis and reporting format for clinical treatment utilization and outcomes,” Co-Investig., 9/09–9/10. 49. HRSA C76HF19883, "Health care and other facilities (Butler Hospital's Center for Advanced Diagnostics and Therapeutics In Alzheimer's Disease)," Progr. Dir.; 9/10-9/11, $198,000. 50. NIMH R21 MH091508, "Childhood Maltreatment: Epigenetic Modulation of the Glucocorticoid Receptor," Co- Investig., 4/11-3/13; $388,694. 51. NeoSync, Inc. “Evaluation of Low Emission NeoSync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter Randomized, Double-Blind, Sham-Controlled, Trial,” Co-Investig., 4/11- 4/14.
UNIVERSITY TEACHING ROLES
University of Michigan
Teaching assistant, "Psychology 442: Motivation and behavior," Dept. of Psychology, 1973-74. Student preceptor, "Freshman physical diagnosis," Schl. of Medicine, 1978.
Yale University
Supervisor/preceptor, 3rd- and 4th-year Yale medical student clerks, 1982-96. Supervisor, Yale psychiatry residents and fellows (PGY-2 - PGY-6), 1982-96. Evening supervisor, Yale-New Haven Hospital Emergency Room (Psychiatry) and Connecticut Mental Health Center Walk-In Service and Administration, 1983-96. Faculty, "Anxiety Disorders" (elective for PGY-3-5 Yale psychiatry residents), 1983. Lecturer, "Psychopathology and Treatment Modalities" (for 3rd- and 4th-year Yale medical student clerks, 1984. Faculty, PGY-2 Neuropsychopharmacology course, 1985-91. Faculty (plenary group interviewer and examiner), "The Clinical Interview in Psychiatry: Techniques and Application" (Department of Psychiatry Continuing Medical Education Program), 1985-90, 1992. Lecturer, PGY-2 Introductory Psychopharmacology course, 1986-96. Faculty (workshop leader), Medical Interviewing workshops (for 1st and 2nd-year Yale medical students), 1986-87; 1995. Faculty (seminar group leader), "Psychiatry 101: The Patient" (for 1st-year Yale medical students), 1987-91. Course Director, Clinical Psychopharmacology Advanced Practicum (Division of Mental Hygiene, Yale University Health Services), 1989-91. Course Co-Coordinator, "Psychopathology and the Neuroscience Basis of Psychiatry" (for PGY-2 Yale psychiatry residents), 1991-92. Course Director, PGY-2 Integrated Psychopathology course, 1992-94. Faculty (examiner), PGY-3,4 Clinical Interview Examination, 1993-96. Lecturer, "Overview of Somatic Treatments in Psychiatry" (in "Models of Care", for Yale School of Nursing MSN candidates), 1993-95. Lecturer, "Mood Disorders" (in "Psychopathology and Human Behavior II", for Yale School of Nursing MSN candidates), 1994-95. Lecturer, PGY-3 Psychopharmacology course, 1995-96.
Connecticut Valley Hosp (in affiliation with Yale University and the State of Connecticut, Department of Mental Health), Middletown, CT
Course Director, "Diagnosis, Clinical Syndromes, and Management," 1983-1996. Course Director, "Research Perspectives in Biological Psychiatry," 1983-1996. Course Director, "Practicum in Advanced Clinical Psychopharmacology," 1983-1996.
44
Lawrence H. Price, MD
Brown University
Supervisor/preceptor, 3rd- and 4th-year Brown medical student clerks, 1996-. Supervisor, Brown psychiatry residents and fellows (PGY-1 - PGY-6), 1996-. Doctor-on-call supervisor, Butler Hosp. Patient Assessment Service, 1996-. Lecturer, PGY-2 Seminar Series, 1996-2002. Visiting faculty (examiner), Dartmouth Dept. of Psychiatry Mock Board Examination, 1996. Lecturer, PGY-3 Neuropsychiatry Seminar, 1997-2002. Lecturer, PGY-4 Seminar Series, 1997-2002. Residency Track Coordinator, Research, 1997-2000. Director, Clinical Case Conference Series, Butler Hosp., 1997-. Lecturer, "Neural regulation of affect and mood" (in "Biomed 370: The Human Brain and Behavior", for 1st-year Brown medical students), 1998-2004. Faculty, Combined Treatment T32 Postdoctoral Fellowship Core Seminar Series, 1998-2002, 2010. Faculty advisor, undergraduate honors thesis (Dept. of Neuroscience), 2001-2002. Invited faculty, Residents Journal Club, 2002-2010. Leader, "PGY-4 Advanced Topics in Psychiatry Seminar", 2003-. Faculty, PGY-1,2 Psychopharmacology Seminar Series, 2003-. Faculty, PGY-3 Psychopharmacology Seminar Series, 2003-. Lecturer, "The neurobiology of mood disorders;" "The treatment of mood disorders" (in "Biomed 365: The Human Brain and Behavior", for 1st-year Brown medical students), 2005-. Lecturer, "Mood Disorders: Phenomenology and Overview" (in "The Neurobiology of Disease," Dept. of Neuroscience), 2008. Leader, "PGY-1-4 Current Issues in Psychiatry Seminar", 2010-.
University of Rhode Island
Field supervisor, University Year for Action, 1999.
Butler Hospital
Leader, Attending Consultation Rounds, 2012-.
45